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ABSTRACT 
 
Effects of Cytosine-phosphate-Guanosine Oligodeoxynucleotides (CpG-ODN) on 
Vaccination and Immunization of Neonatal Chickens. (December 2004) 
Adriana Barri, D.V.M., Universidad Nacional Autónoma de México 
Chair of Advisory Committee: Dr. David J. Caldwell 
 
 
 
 The objective of this investigation was to evaluate the effects of administering 
CpG-ODN to commercial strain chickens as a potential adjuvant to vaccination against 
Salmonella, Eimeria spp., and Newcastle disease virus, or immunization to bovine 
serum albumin (BSA). During Experiment 1,  which evaluated the dual application of 
CpG-ODN and a Newcastle disease virus vaccine, in the first of three replicate trials, 
on day 28 of the experiment, animals in the Vaccine + CpG 1& 14 experimental group 
were observed to have the highest levels of (p<0.05) anti-NDV IgG in serum.  These 
levels were elevated above levels in animals from all other experimental groups. This 
suggestion for an adjuvant effect associated with CpG-ODN administration was not 
supported in the remaining two trials of experiment 1. 
 Experiment 2 evaluated the potential for CpG-ODN to adjuvant a commercial 
live oocyst coccidial vaccine when applied by an oral route to neonatal broiler 
chickens. Overall, when body weight gain during challenge, development of intestinal 
lesions, and anti-Eimeria IgG levels were evaluated, vaccine administration alone was 
demonstrated to provide the best measure of protection among animals in all 
 iv
experimental groups, including those receiving either CpG-ODN or Non CpG-ODN.
 Experiment 3 investigated the simultaneous administration of CpG-ODN or 
Non-CpG ODN and a commercially acquired Salmonella typhimurium vaccine to 
SCWL chickens. Similar to experiments 1 and 2, antigen specific IgG responses in 
serum and indices of protection against field strain Salmonella challenge were variable 
and inconsistent. 
 Anti-BSA IgG levels were compared in broiler and SCWL chickens immunized 
against BSA by a drinking water route of administration alone, or in combination with 
two different concentrations of CpG-ODN or Non CpG-ODN in experiment 4. The 
only observation where CpG-ODN and BSA co-administration resulted in anti-BSA 
IgG levels that were elevated above BSA alone immunized chickens was measured in 
broilers at day 19 post-final immunization.  
 Taken together, given the variable results reported in this investigation related 
to the co-administration of ODN and vaccine or protein antigen, these data are largely 
inconclusive for suggesting that CpG-ODN can effectively adjuvant humoral immune 
responses in commercial strain chickens. 
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CHAPTER I 
 
INTRODUCTION 
 
⎯The poultry industry represents one of the most important sectors in all modern 
animal agriculture within in United States. It is considered to be a $22 billion industry 
that employs about 240,000 workers (U.S.D.A., 2004). It is one of the fastest growing 
segment of the animal industry, thus, regardless of the product produced, most of the 
systems employed by this industry involve intensive rearing were large numbers of 
birds, usually flocks with tens of thousands, are raised inside a closed house (Sharma, 
1999). To control disease conditions under these dense and intensive rearing 
environments, vaccines represent an important and invaluable prophylactic and 
therapeutic strategy for commercial producers (Sharma, 2003). The commercial poultry 
industry relies heavily vaccines to protect chickens and turkeys against many pathogens 
that threaten poultry health and the subsequent overall economics of the industry. 
Vaccines in the poultry industry are needed in order to induce protection against 
infections by stimulating lymphocytes to produce antibodies or cytokines and 
differentiate into memory cells so that subsequent encounters with the same pathogens 
will be resolved quickly and efficiently (Abbas et al, 2000; Bermudez and Stewart-
Brown, 2003; Sharma, 2003). The fundamental task of the immune system in such a 
scenario is to protect the host against invading microorganisms or pathogens through a 
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cooperative approach involving both innate and adaptive immunity. Innate immune 
responses are typically activated by innate system cells, such as macrophages, 
heterophils, or dendritic cells, which then act in concert to either kill the invading 
microbe or augment and trigger an appropriate adaptive immune response. Because 
innate immune cells lack the highly specific antigen receptors found on T and B cells, 
they rely on surface membrane proteins known as pattern recognition receptors (PRRs). 
PRRs have the ability to detect surface components of microbial pathogens known as 
pathogen associated molecular patterns (PAMPs). PAMPs recognition by PRRs in this 
setting is an indication of a threat to the host in the form of potential infection. Such 
recognition activates appropriate defense pathways in the innate system to either remove 
the pathogen or stimulate the adaptive system to act upon the pathogen for its ultimate 
removal. Cytosine-phosphate-guanosine (CpG) motifs naturally present in bacterial 
DNA represent one of the most recent examples of substances that influence adaptive 
immune responses by activating the innate immune system. CpGs are 6-8 base 
nucleotide motifs consisting of an unmethylated CpG dinucleotide that induces cells of 
the innate immune system to increase phagocytosis, pro-inflammatory cytokine 
production, activation of NK cells, and increase nitric oxide generation by macrophages. 
The most critical line of defense against pathogens in an organism is the 
mucosal associated lymphoid tissues (MALT), which are comprised of the bronchial, 
salivary, genitourinary, nasopharyngeal, and gut associated lymphoid tissues (GALT) 
(Lillehoj and Trout, 1996; Yun et al., 2000; Bar-Shira et al., 2003). The last two, 
although separated, are important and integrated immune systems. They are considered 
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to be very important in the protection of the organism because these are the primary 
routes of entrance for any pathogen into the host (specifically digestive or respiratory) 
(Bar-Shira et al., 2003). The ability of CpG-oligodeoxynucleotides (ODN) to act as 
vaccine adjuvants has been explored extensively in recent years in mammals but very 
little research has been conducted along these lines in commercial poultry. In recent 
years, DNA vaccines or DNA extracts from bacteria have been recognized as having 
tremendous potential for improving vaccination strategies in commercial poultry 
against different pathogens. The objective of this investigation was to evaluate the 
administration of CpG-ODN as a potential oral or mucosal adjuvant to commercially 
available vaccines against Salmonella, Eimeria spp., and Newcastle disease Virus, and 
a common protein antigen, bovine serum albumin (BSA), used frequently as an 
immunogen in poultry by our laboratory. Measured experimental outcomes included 
the level of antibodies produced and protection against subsequent clinical challenge in 
experimental animals following immunization and vaccination procedures evaluated in 
this study. 
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CHAPTER II 
 
LITERATURE REVIEW 
 
Basic Concepts of Immunology 
The term immunity comes from the Latin word immunitas which originated in 
the Roman Empire where it was initially used to signify freedom from the taxes, 
services, and prosecution for Roman senators for which other citizens were forced to 
comply. The emperors frequently granted it to special classes of persons or to whole 
states (Abbas et al, 2000). Today, in medical terminology immunity refers to the 
condition in which an organism can resist disease. The immune system is the only 
defense of an organism against infectious diseases (Lynn et al., 2003). Different factors 
may affect its response. The immune system consists of coordinated responses between a 
stimulus (antigen, antigen’s nature, route and dose), external factors (diet or stress), and 
internal factors including genetics (MHC expression or not, T and B cell repertoire, etc), 
which make a living animal capable of establishing an effective immune response 
against the stimulus (Abbas et al., 2000). 
Any substance that is capable, under appropriate conditions, of inducing a 
specific immune response and of reacting with the products of that response, like 
antibodies or specifically sensitized T-lymphocytes, is an antigen (Ag). Antigens may be 
soluble substances, such as toxins, foreign proteins, or particles derived from bacteria or 
other infectious pathogens and tissue cells. Only the portion of the protein or 
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polysaccharide molecule known as the epitope reacts with the variable region of the 
antibody or a specific receptor on a lymphocyte. The ability for an epitope or antigen to 
elicit immune responses is known as immunogenicity (Abbas et al., 2000).  
Innate and adaptive are two integrated but distinct forms of immunity that exist in any 
organism or animal. Innate or nonspecific immunity is the organism’s first generalized 
line of defense against all pathogens (Lynn et al., 2003). Innate immunity is composed 
of 1) physical and chemical barriers including skin, tears, mucous, and saliva, 2) 
phagocytic cells such as heterophils, macrophages, and dendritic cells, and 3) 
inflammation of tissues once an organism is injured or after a pathogen has initiated an 
infection (Abbas et al., 2000). These innate immune mechanisms usually help prevent 
the entrance and spread of different pathogens, but when the infection can not be 
controlled completely, specific or adaptive immunity is activated or engaged. The 
adaptive/acquired or specific immune system responds through lymphocytes and other 
accessory cells (Abbas et al., 2000). Unlike innate immunity, it responds only after the 
pathogen is present, it is much more specific, and has memory facilitating it to react 
faster and stronger when a repeated exposure to the pathogen occurs. Importantly, a very 
important characteristic of adaptive immunity is that it does not attack normal body 
components, only those substances it recognizes as foreign and non-self. The most 
important cells of the adaptive immune system are lymphocytes or B and T cells (Abbas 
et al., 2000). 
It is well supported that the onset of the innate immune responses starts once an 
antigen has entered into the organism. The first cells to migrate to the site of infection 
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are the phagocytic cells, macrophages, dendritic cells, and heterophils, all of which are 
important components of the innate immune response and the inflammatory response 
(Qureshi, 1998; Ahmad-Nejad et al., 2002)). Innate immune responses are initiated with 
the interaction between these cells and the pathogen. They can ingest the pathogen 
through pinocytosis, phagocytosis, or receptor mediated endocytosis (Qureshi, 1998; 
Thery and Amigorena, 2001). The receptors that activate innate cells and initiate these 
actions are known as pattern recognition receptors (PRRs). There are different kinds of 
PRRs: 1) Secreted (mannan binding lectin), 2) Endocytic (macrophage mannose 
receptor), and 3) Signaling, including the toll like receptors (TLRs), which associate 
with pathogen’s surface structures called pathogen associated molecular patterns 
(PAMPs). PAMPS include mannan components of yeast cell walls, lipopolysaccharide 
(LPS) from Gram-negative bacteria, lipoproteins, peptidoglycans, and DNA containing 
unmethylated CpG-ODN (Medzhitov and Janeway, 1997; Aderem and Underhill, 1999; 
Thery and Amigorena, 2001; Lynn et al., 2003). PRRs can also be expressed 
intracellularly like protein the kinase receptor produced under viral infection or some 
TLR like TLR9 (Janeway and Medzhitov, 2002). The PAMP-PRR interaction helps with 
the internalization of the antigen, its enzymatic degradation, and its further presentation 
through the MHC class I or II molecules to the surface, for activation of the adaptive 
immune response by stimulating naive T cells and B cells to proliferate and differentiate 
to eliminate the antigen (Aderem and Underhill, 1999; Abbas et al., 2000). 
Internalization of the antigen/pathogen can be also triggered through the opsonization of 
the antigen with antibodies through the recognition of the antibody’s constant region 
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receptor and the microbes’ cell surface receptors, or through complement receptors that 
recognize complement fragments on the pathogen’s cell surface (Abbas et al., 2000). 
The adaptive immune response consists of two separate responses: humoral and 
cell mediated responses. Humoral immunity consists of the activation of B cells which 
are responsible for the production of immunoglobulins. Immunoglobulins are antibodies 
and are present mainly in serum, cell surfaces, egg yolk, bile and mucosal secretions 
(Abbas et al., 2000). There are different means by which antibodies can react to a 
pathogenic organism: 1) Neutralization: prevent the pathogen from attaching to surface 
receptors of target cells thereby inhibit replication (virus), 2) Opsonization: antibodies 
attach to the microbes surface and facilitate macrophages and phagocytic cells to 
internalize and destroy such pathogens, and 3) Complement activation: (classic 
pathway), antibodies bind to the surface of the pathogen and activate the complement 
proteins, which are bound to phagocytes receptors facilitating the phagocytosis and 
destruction of it (Abbas et al., 2000). There are three main isotypes of immunoglobulins 
in chickens: IgA, IgG(Y), and IgM. This differs with mammals in that most mammals 
have five standard isotypes. IgM is found on the surface of most B cells, and is the 
usually the antibody that predominates in a primary immune response. Class switching 
of an antibody occurs when IgM producing cells stop producing this isotype and 
“switch” to the production of another isotype like IgG or IgA. The cytokines that 
stimulate the B cells to do the class switch are IL-4 and IL5. IgG is the predominant 
immunoglobulin circulating in blood. IgA is involved in mucosal immunity (Castro and 
Powell, 1994; Staeheli et al., 2001). T lymphocytes or T cells exist as two different 
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classes of cells 1) T helper Lymphocytes (CD4+), whose main function is to secret 
cytokines for regulating immune responses; and 2) T cytotoxic Lymphocytes (CD8+), 
which destroy viral infected cells (Abbas et al., 2000).  
Antigen presenting cells, such as dendritic cells, B cells and macrophages, are the 
cell populations that integrate the innate and adaptive immune systems. In their 
immature form, these cells phagocytose and degrade pathogens and express the degraded 
microbial peptides in major histocompatibility complex (MHC) class I or II molecules 
for presentation to lymphocytes (Abbas et al., 2000; Janeway and Medzhitov, 2002). 
After the identification of the pathogen, the non-mature antigen presenting cells of the 
innate system, control the acute innate host response by phagocytosing and then killing 
the invading microbe by producing oxygen intermediates (superoxide anion, hydrogen 
peroxide, chloramines and hydroxyl radicals) and secreting proteolytic enzymes (Abbas 
et al., 2000). The end product of this microbial recognition is the activation of 
intracellular signaling pathways that initiate maturation of the APC with cellular 
processes such as a) production of inflammatory cytokines such as TNF-α, and IL-1β, 
effector cytokines like IL-12 and type I interferon, b) up regulation of co-stimulatory 
molecules like CD80 and CD86 (regulated by transcription factor NFκB), and c) 
presentation of the antigenic peptides through their expression in MHC class I or II 
molecules for antigen presentation to the acquired immune system (Swaggerty et al 
2004; Wagner, 2002).  
The most important outcome from the activation of naive T cells through the 
presentation of the antigen-MHC complex is the proliferation of the antigen-specific T 
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cell and then the differentiation into effector and memory cells (Wagner, 2002). The 
origin of the pathogen will determine the class of MHC molecule used. Any extracellular 
antigen or protein, including bacteria (Salmonella spp) or parasites (Eimeria spp), will 
be presented through an MHC class II complex and recognized by a CD4+ T cell. Any 
antigen or protein with an endogenous origin or presence in the cytosol, such as virus, 
will be presented through the MHC class I pathway and will be recognized by CD8+ T 
cells. T cells become activated and initiate the production of different cytokines that will 
function in the effector stages of cell mediated immunity. T cells will also increase the 
expression of receptors for different cytokines as well once activated. One of the most 
important cytokines secreted for proliferation of T cells is IL-2, an autocrine cytokine, 
which acts as a growth factor (Abbas et al., 2000; Thery and Amigorena, 2001). 
Depending on the T cell phenotype activated (CD4+ or CD8+); a specific differentiation 
pathway will follow (Castro and Powell, 1994). CD4+ T cells differentiate into effector 
TH cell subsets that produce or secrete 2 different profiles of cytokines: Th1 and Th2 
cells. Th1 cells, secretes IL-2 and IFNγ and therefore promote the cell mediated immune 
response. Th2 cells secrete IL-4, IL-5, IL-6, and IL-10 promoting the humoral immune 
response (Abbas et al, 2000; Staeheli et al., 2001; Davison, 2003). When CD8+ T cells 
recognize the antigen presented, they differentiate into cytotoxic cells (CTLs) which 
have the capacity to lyse and kill cells expressing foreign antigen in MHC I molecules. 
The most important function of the CD4+ effector cells is to activate phagocytic cells and 
lymphocytes. The expression of co stimulators helps T lymphocytes to work in harmony; 
the co stimulators involved in T cell activation are CD28 (on T cell surface) which binds 
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to B7-1 or CD80 and B7-2 or CD86 expressed mainly on professional APC (Abbas et al, 
2000).  
B lymphocytes require stimulation similar to T cells in order to proliferate and 
differentiate into antibody producing cells, plasma cells, or memory cells (Castro and 
Powell, 1994). According to Bernasconi and Fagarasan, there are two subsets of B cells. 
Conventional B cells, the B2 subgroup which are activated with the participation of Th2 
cells, and another subset referred to as B1 cells which are activated independently of T 
cell cooperation (Fagarasan and Honjo, 2000; Bernasconi, 2002). When B cells are 
activated, they proliferate into effector or plasma cells and into memory cells (Fagarasan 
and Honjo, 2000; Abbas et al, 2000; Bernasconi, 2002). Different pathways to stimulate 
B cells into proliferation and differentiation exist. First is the scenario where B naive cell 
activation occurs in the presence of the antigen. The antigen binds to the 
immunoglobulin present on the B cell’s surface, and with the help of co stimulation by 
antigen-specific T cells through the interaction of CD40 with its ligand, and the secretion 
of cytokines (T-dependent pathway used by B2 cells), activation occurs. A second 
scenario occurs in absence of the antigen through microbial derived products such as 
LPS or CpG-ODN, which stimulate B cells via TLR4 and TLR9 (T-independent 
pathway used by B1 cells; (Bernasconi, 2002).  
Cytokines are essential effector molecules of innate and acquired immunity that 
initiate and coordinate cellular and humoral responses directed to eradicating pathogens 
(Castro and Powell, 1994). Cytokines are active proteins that are secreted by different 
immune cells (T cells, B cells, macrophages, and dendritic cells) in order to regulate 
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other cells. They are classified in different groups, including, interferons (IFN), tumor 
necrosis factor (TNF), interleukins (IL), and chemokines. Cytokines can regulate 
immune responses by attaching to the surface of the cells and initiating signaling 
pathways (Paul et al., 1994; Staeheli et al., 2001). Some of the chicken cytokines that 
have been completely characterized to date are IFNα, IFN β, IFNγ, IL1β, IL2, IL6, IL8 
IL15, IL16, IL17, and IL18 (Staeheli et al., 2001; Lillehoj et al., 2004). IL-6, is 
produced by T and B cells, endothelial cells, and macrophages, among others. Its 
secretion is induced by LPS, and can also be found in serum, ascites fluids, and in 
thymus tissue sections of chickens. As described above, T helper cells, depending on the 
kind of cytokines they secrete, are separated into two classifications: Th1 and Th2 cells. 
However, none of the Th2 cytokines homologs for avian cytokines (IL-4, IL-5, IL-10, or 
IL-13) have been characterized to date (Staeheli et al., 2001; Davison, 2003). On the 
other hand, one of the cytokines secreted by Th1 cells, under stimulation of IL-12 and 
IL-18 (produced by macrophages, dendritic cells, and B cells) is IFNγ, which activates 
macrophages and enables the destruction of pathogens (Staeheli et al., 2001). Studies 
have been performed evaluating cytokine expression during Eimeria spp infection in 
birds. Some reports show IL-6 is observed in serum of chickens that were infected with 
Eimeria (Staeheli et al., 2001). Using standard PCR, there are also studies that report the 
increase of mRNA expression of IFNγ at the infection site in the gut of diseased birds. 
Other studies have shown a great inflammatory response during the infection with 
Eimeria mediated by chemokines, cytokines and TGF synthesized and secreted at the 
local site of infection (Staeheli et al., 2001). For viral infections, including infection by 
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Newcastle disease virus, reports describe that the oral administration of IFNα was able 
to diminish the state of the disease or at least improve the health in infected chickens. 
When IFNα was administered in a higher concentration through the drinking water, 
birds were reported to not lose weight due to the disease and the lesions in tracheal tissue 
were “strongly reduced” (Staeheli et al., 2001).  
Cytosine- phosphate- Guanosine Oligodeoxynucleotides (CpG-ODN) 
Prior to 1984, bacterial DNA was largely considered to be immunologically non-
reactive. Around this time, a series of investigations utilizing bacterial DNA isolated 
from Mycobacterium bovis first began to describe the potential stimulatory effects of 
bacterial DNA on the immune system (Hacker, 2002). By demonstrating direct and 
indirect stimulation of B cells and stimulation of NK cells to secrete INF-γ and the 
initiation of anti-tumor activity, CpG-ODN were first described as being the 
immunostimulatory component of bacterial DNA by Krieg and co-workers (Krieg et al., 
1995, 1996; 1999). In these investigations CpG-ODN were characterized as being 
specific sequence contexts of oligodeoxynucleotides (ODNs) with unmethylated 
cytosine-phosphate-guanosine (CpG) dinucleotides. CpG-ODN are 6-8 base nucleotide 
motifs consisting of CpG dinucleotides linked together by phosphodiester bonds and 
usually flanked by two 5’ purines and two 3’ pyrimidines. Since they are polyanions and 
cannot diffuse across cell membranes freely, ODN uptake into the cells requires the 
participation of a voltage-gated channel (Krieg, 2002). These unmethylated 
dinucleotides are expressed approximately 20 times more frequently in bacterial than in 
vertebrate DNA and the vertebrate cytosine residues are more frequently methylated at 
   
13
position 5. These differences characterize CpG-ODN as PAMPs and thus enable 
vertebrates to protect themselves against invading pathogens (Klinman et al., 1996). 
Hemmi and Bauer, respectively, reported that CpG DNA is recognized by a member of 
the Toll-like receptor (TLR) family which triggers the host’s innate immune system. 
CpG-ODN present in bacterial DNA represents one of the most recent examples of 
PAMPs that influence adaptive immune responses by activating the innate immune 
system (Hemmi et al., 2003). 
The chemical structure of CpG-ODN greatly influences their ability to stimulate 
innate system cells. Changes in the bases flanking the CpG dinucleotides (purines and 
pyrimidines) have a great influence on the response because they influence recognition 
by the innate immune system. Although CpG-ODN uptake involves the binding to cell 
surface proteins with a non specific antigen-receptor, the immunostimulatory effects of 
CpG-ODN are activated by binding to an intracellular receptor, TLR9 (Krieg, 2002). 
Although this is not well understood, it is possible that TLR-9 may require a specific 
sequence in order to recognize CpG-ODN as a PAMP and bind to it as an antigen-
dependent response according to the sequences that are surrounding the CpG 
dinucleotides (Zhao et al., 1996; Pisetsky and Reich, 1999; Dalpke et al., 2002; Krieg, 
2002). CpG-ODN in humans and mice, for example, must have specific nucleotide 
sequences in order to trigger an immune response. The sequence GACGTT has been 
shown to be the most immunostimulatory sequence in mice and rabbits, however it is 
inhibitory for other species and distinct from the most stimulatory sequence in humans 
GTCGTT (Rankin et al., 2001; Vleugels et al., 2002). Research into the 
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immunostimulatory effects of CpG-ODN have not been limited to mice, rabbits, or 
humans, and have included sheep, horses, pigs, dogs, and cats, thus demonstrating that 
responsiveness to unmethylated bacterial DNA sequences is a phenomenon conserved 
across many species (Rankin et al., 2001). Some research groups have proposed 
different consensus base sequences for immunostimulatory DNA sequences in different 
species. They found that the main characteristic of ODN stimulating an immune 
response was the presence of a GTCGTT motif. They reported that three GTCGTT 
motifs within the ODNs had a stronger and consistent stimulatory effect, while ODNs 
with only one or two did not activate the immune cells as consistently (Rankin et al 
2001; Vleugels et al., 2002; He et al., 2003). They also found that some ODNs can have 
in the same structure, three distinct CpG motifs: GTCGTT + GACGTT + TGCGTT. 
This proposed sequence combination was shown to be stimulatory to immune cells from 
goats, horses, pigs, dogs, cats, chickens, rats, and rabbits, but not stimulatory for 
leukocytes from sheep or mice (Rankin et al., 2001). Most of the immune enhancing 
potential in different species is strictly CpG dependent and inversions to GpC abolish 
this activation (Ahmad-Nehad et al., 2002). Modifications made in the natural backbone 
chemistry of the CpG may also affect the immunostimulatory effects of the bacterial 
DNA by enhancing or deteriorating such effects. Natural ODNs are bound by 
phosphodiester bonds which make them very unstable and susceptible to endogenous 
nucleases found in biological fluids. These enzymes, present in responding immune 
system cells, quickly degrade CpG-ODNs by hydrolyzing the phosphodiester backbone, 
reducing the potential for immunostimulation. To improve stability necessary to allow 
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investigation into the immunostimulatory effects of CpG-ODN, synthetic CpG-ODN 
have been designed. However, such modification of CpG-ODN structure has proven to 
be complicated because many factors have been shown to influence both their activity 
and stability. Synthetic ODNs or analogs differ from the native ones by the substitution 
of a molecule of oxygen (O-) at the phosphate group in the nucleotide. As such, these 
analogs are more resistant to nucleases, by increasing their stability against degradation. 
Successfully created analogs that have been reported to date include: a) 
Methylphosphonate ODN; b) Phosphoramidate ODN; c) Phosphorothioate ODN; and d) 
(N3’---- P5’) Phosphoramidate (Gallo et al., 2003). The most common ODN recently 
reviewed in the literature have contained the phosphorothioate backbone due to their 
ability to increased nonspecific binding to different proteins, increased efficiency of 
binding to cell membranes, and a higher degree of cellular uptake. ODN with this 
backbone are taken up much more efficiently than ODN with the phosphodiester 
backbone and are more efficiently endocytosed than ODN with a methylphosphonate, 
besides, their half life in vivo is 48 hours while the half life of a CpG-ODN with a 
phosphodiester backbone is 5 minutes (Pisetsky and Reich, 1999; Gallo et al., 2003; 
Krieg, 2002). According to the susceptibility to degradation which is determined by the 
backbone, the ability to induce proliferation of B cells, activate macrophages, NK cells 
or other immune cells, will be either enhanced or decreased (Krieg, 2002; Zhao et al., 
1996; Pisetsky and Reich, 1999). Krieg describes that when phosphorothioate CpG-
ODN are administered IV or SC they tend to concentrate in liver and kidney in high 
levels, and in less concentrations in spleen and bone marrow.  
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 The following scenario can be used to describe how CpG-ODN stimulate the 
innate immune system during a bacterial infection. CpGs cross the cell membrane via 
sequence-non-specific receptor-mediated endocytosis. Once the bacterium is ingested by 
a macrophage and its DNA is degraded into ODN inside the cell, CpG-ODN is 
recognized by TLR-9. Recognition through TLR-9 will induce an immune response 
involving both innate and adaptive immune system cells (Krieg, 2002). The cellular 
activation by TLR-9 binding proceeds through a signaling cascade involving myeloid 
differentiation marker 88 (MyD88), IL-1R-associated kinase (IRAK), tumor necrosis 
factor receptor associated factor 6 (TRAF 6), nuclear factor kappa B (NF- κΒ) 
translocation, and up-regulation of genes involved in host defense. After this initial 
response, the triggering of TLR by specific CpG-ODN, results in TLR-9 specific 
immune responses (Takeshita et al., 2001; Medzhitov, 2001; Kaisho and Akira, 2002). 
CpG-ODN can also act directly on B cells triggering cytokine production (IL-6, and IL-
10), and immunoglobulin secretion. They’ve also been shown to activate dendritic cells 
to produce pro-inflammatory cytokines like IL-12 and stimulate antigen-specific T-cells, 
and proliferation of B cells (Medzhitov, 2001; Krieg, 2002). By such mechanisms, CpG-
ODN are proposed to be important elements for eliciting mucosal and systemic immune 
responses in many animal species (Krieg et al., 2001). CpG-ODN stimulates the 
production of IFNγ more than IL-12, and IL-10 functions as a counter-regulatory 
towards IL-12 secretion (Krieg, 2002). Activated B cells by CpG-ODN increase also 
cytokine expression of the Fcγ receptor, MHC II, CD80, and CD86 (Krieg, 2002). 
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Vaccines 
The poultry industry is one of the most important sectors of all modern 
agricultural systems in United States. The value of broilers alone produced during 2001 
was $16.7 billion (U.S.D.A., 2004). Regardless of the product produced, whether it be 
meat type chickens or turkeys, table eggs, or other specialty products, most of the 
systems employed by the industry involve intensive rearing were large numbers of birds, 
usually flocks with tens of thousands, are raised inside a closed house (Sharma, 1999). In 
such environments, the possibility of spreading disease among animals in a flock is 
much higher, therefore biosecurity measures must be followed and strict vaccination 
schedules must be maintained in order to diminish the possibility of disease outbreaks. 
Bacteria, virus, fungi, and parasites are potential pathogens of poultry. Some may cause 
severe clinical disease and death in less than 72 hours, while others may only cause sub 
clinical infections. In both instances, economic losses for growers and the industry in 
general are experienced (Bermudez and Stewart-Brown, 2003). To control disease 
conditions within these intensive rearing environments, vaccines represent an important 
and invaluable prophylactic and therapeutic strategy for commercial producers (Sharma, 
2003). The commercial poultry industry relies heavily on vaccines to protect chickens 
and turkeys against many pathogens that threaten poultry health and the subsequent 
overall economics of the industry. Vaccines in the poultry industry are required to 
induce protection against infections by stimulating lymphocytes to produce antibodies or 
cytokines, and differentiate into memory cells so that subsequent encounters with the 
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same pathogens will be resolved quickly and efficiently (Abbas et al, 2000; Bermudez 
and Stewart-Brown, 2003; Sharma, 2003)) 
The term vaccine was first employed by Edward Jenner in 1796 after his 
successful prevention of infection by the smallpox virus. Approximately one hundred 
years later, in 1880, Louis Pasteur discovered that by allowing bacteria, in this case, 
Pasteurella multocida , the etiological agent of Fowl Cholera, to grow for a long period 
of time in the cell culture, it would become attenuated or weakened, and thus work 
effectively and without risk as a preventive vaccine for chicken and humans diseases 
(Gordon, 2003). Later, Pasteur extended this concept to other pathogens and found the 
cure for rabies. By inoculating a boy bitten by an infected dog with his vaccine, he was 
able to prevent the appearance of the clinical signs and symptoms of rabies. This 
procedure is still the only cure for this disease (Abbas et al., 2000).  
In some cases, a vaccine alone will cause a mild form of disease, but will usually 
not endanger the life of the animal. Vaccinations are used frequently and can start at 
day-of-hatch in poultry, and in some cases even before hatch, through in ovo vaccination 
(Bermudez and Stewart-Brown, 2003). Whenever a vaccine program is initiated, 
endemic diseases, flock history, distance from other birds or other houses or other 
productions, age, genetic background of the birds, and other environmental factors 
should be considered. It is important not to vaccinate when the pathogen is not endemic 
in order to avoid the introduction of a pathogen into a “clean” environment (Sharma, 
1999; Brigitte, 2004). The protection of a flock can also be enhanced through 
vaccination of breeders in order to maximize maternal antibodies that will be passed 
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through the egg for protection in newly hatched chicks (Bermudez and Stewart-Brown, 
2003). Maternal antibodies can circulate in the chick for up to 3 weeks, hopefully giving 
the neonatal animal time to allow for further maturation and development of the immune 
system (Bermudez and Stewart-Brown, 2003). While an initial administration of most 
vaccines usually generate immunologic memory, a secondary or boost administration of 
the same vaccine, is often required. Some vaccines however, like Marek’s Disease virus 
vaccine, can elicit lifelong immunity following a single administration (Sharma, 1999). 
Specific immune defenses against different pathogens are required. When a 
vaccine is being developed, different aspects should be considered, such as overcoming 
immune evasion strategies used by persistent pathogens, major histocompatibility 
complex molecule expression, integration of the pathogen genome in host DNA, 
antigenic variability of the pathogen, latency, age and genetic background of the host, 
among other things (Brigitte, 2004). 
Vaccines also need to elicit strong CD4+ and CD8+ T cell responses. To do so, 
attenuated pathogens have traditionally been the choice for vaccines; unfortunately, such 
vaccines also expose potentially uncontrolled risks (Brigitte, 2004). The dose and route 
of administration of a vaccine are also very important, if applied through the incorrect 
route or in an insufficient concentration, the vaccine may not succeed in generating 
immunity. A vaccine may require several administrations as well. The different routes of 
administration of vaccines include intra muscular (IM), subcutaneous (SC), wing web 
puncture, and aerosol spray (Bermudez and Stewart-Brown, 2003). Oral (through 
drinking water or gavage), intranasal, and ocular (eye drop) immunizations are good 
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routes for generating mucosal immunity, and they can also elicit a systemic humoral 
responses (Abbas et al., 2000). While in mammals, it is widely believed that oral routes 
of administration of antigen may lead to a state of systemic immune tolerance. More 
recent reports however, describe that in chickens of immunocompetent age, oral antigen 
administration with our without adjuvant results in robust systemic as well as local, 
mucosal immune responses (Klipper et al., 2000, 2001; Ameiss et al., 2004). Through 
the use of different antigen delivery systems that vary from soluble proteins with 
mucosal adjuvants to attenuated recombinant bacterial and viral vectors, immune 
responses with different effector characteristics can be induced.  
There are several different types of vaccines currently used in commercial 
poultry operations. These include attenuated and inactivated vaccines that are usually 
used for bacterial and viral pathogens. These are vaccines where the intact pathogen is 
treated in such a way (prolonged growth in cell cultures, heat, or chemical substances) 
that it can no longer produce clinical disease. The goal of such vaccines is to persist in 
the host long enough to imitate the threatening signals normally expressed by pathogens 
and trigger both innate and adaptive immune response (Abbas et al, 2000). In addition to 
viral and bacterial vaccines of this type, several live and attenuated vaccines against 
coccidia species are commercially available that are composed of oocysts from distinct 
species of Eimeria (Lillehoj and Trout, 1996; Yun et al., 2000). Another type of vaccine, 
consist of subunit vaccines, purified antigens. In these vaccines, antigenic portions of the 
pathogen are usually given together with an adjuvant or hapten- carrier conjugates to 
generate immunity in the host. These vaccines are used usually designed for bacterial 
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toxins or polysaccharide antigens. These purified protein vaccines are effective at 
stimulating TH cells and antibody responses by B cells, since they are acquired 
extracellularly as proteins and are expressed through the MHC II pathway of antigen 
processing and presentation. Recombinant proteins obtained from Eimeria acervulina 
have been shown to be good immunostimulatory antigens for cellular and humoral 
responses in natural and passive immunity (Lillehoj et al, 2004). Another type of vaccine 
includes synthetic antigen vaccines which are synthesized in a laboratory following the 
identification of the most immunodominant epitope(s) of a specific pathogen. This is 
possible through the use of recombinant DNA technology and by mutational analysis 
where the peptides are overlapped making it possible for them to be presented and 
recognized (Abbas et al., 2000). According to Sharma (1999), live fowl pox virus and 
turkey herpes virus are common vectors with inserts of genes that encode for 
immunogenic proteins of different avian pathogens such as Newcastle disease virus, 
avian influenza, or infectious bronchitis disease virus (IBDV), to enhance protection in 
the host. In this scenario, live viral vectors represent yet another classification of 
vaccines. Such vaccines consist of the introduction of genes encoding pathogenic 
antigens of a certain pathogen into a vector (which is non pathogenic) and then infecting 
the organism to induce an immune response which typically includes the activation of 
CD8+ cells. However, this can cause the lysis of host cells presenting this antigen even 
though the virus is non pathogenic. Another type of vaccine getting a great deal of 
attention in recent years is a DNA vaccine. These vaccines involve the internalization of 
a plasmid containing a cDNA that will encode the protein antigen of the pathogen within 
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the cytoplasm of transfected cells, and thus induce a good CTL response. Since bacterial 
DNA contains CpG-ODN, it will also be recognized as foreign and an innate immune 
response will be elicited stimulating at the same time a good adaptive immune response 
(Abbas et al, 2000). 
Adjuvants 
Adjuvants are substances that when are administered with an antigen can induce 
a stronger antigen-specific immune response (Sharma, 1999; McCluskie and Weeratna, 
2001a). The selection of an appropriate adjuvant is often as important as the 
development of the vaccine. The most efficacious adjuvants successfully imitate the 
immunogenicity elicited by live pathogens (Kaufmann, 1996). Adjuvants can act in 
different ways, including: a) enhancing the immunological life of the vaccine; b) 
increasing antigen uptake; and c) by improving antigen presentation through MHC 
pathways in APCs. Some adjuvants can be used just as delivery systems with some 
immunostimulatory properties; however the best adjuvants are the ones that are 
immunostimulatory molecules per se, such bacterial toxins, hormones, synthetic CpG-
ODN, and others. Different natural immune markers or ligands, including cytokines and 
chemokines, are now being used to regulate or enhance effector T cell function and 
memory T cell maintenance during vaccination (Kaufmann, 1996). Chemokines 
augment Th 1 and CTL responses increasing a vaccine’s efficacy, however, they are still 
under development. IFNγ for example has shown to be a good adjuvant by increasing the 
antibody responses when administered in a plasmid during the immunization against 
Eimeria acervulina. When given orally IFNγ has also been shown to improve the health 
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in chickens infected with NDV (Staeheli et al., 2001). The FDA will only approve those 
adjuvants that produce the minimal adverse effects in an immunized animal. For 
mucosal immunization the most potent adjuvants described to date appear to be Vibrio 
Cholerae toxin (Ct) and Escherichia coli enterotoxin (Et) (O’Hagan et al., 2001). 
Adjuvants can also determine which type TH cell response will be stimulated, either a 
Th1 –like or a Th2 –like responses. For example, oral administration of a soluble protein 
with Ct as an adjuvant has shown a Th2-type immune response, while the use of CpG-
ODN stimulates a Th1 –like type immune response (Staats et al., 1996; McCluskie and 
Davis, 1998, 1999a; McCluskie et al, 2002; O’Hagan et al., 2001). 
Due to modifications done to pathogenic antigens while developing vaccines, 
some of them may induce a weaker immune response than the original pathogen when 
administered alone by either parenteral or mucosal routes. Under such circumstances, the 
generation of a successful immune response is often accomplished through the use of 
adjuvants. Studies evaluating adjuvant properties demonstrate that adjuvants have the 
capacity to affect the kinetics, duration, amount, avidity, and neutralization capacity of 
antibodies produced during immunization (Hinoshi et al., 1996). It is also known that 
adjuvants affect the specificity of antibody responses by affecting the epitope to which 
the antibody is targeted (Hui et al., 1991). Although, adjuvants have been studied and 
used for many years, the mechanism of action of some is still not well understood. 
Nonetheless, it is firmly believed that adjuvants are as important as the vaccines in some 
instances when it is necessary to induce protection of an animal against disease 
(Weeratna et al., 2000).  
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Some adjuvants exist as delivery systems and have the capacity to form deposits 
of antigens at the site of inoculation. This helps promote a slower release of the antigen, 
thus exposing immune cells to it for a longer period of time. Examples of these types of 
adjuvants are oil (lipid) emulsions and aluminum salts (Weeratna et al., 2000). Another 
class of adjuvants: LPS, CPG-ODN, or monophosphoryl lipid A (MPL), are known as 
immunostimulatory adjuvants. These adjuvants represent PAMPS and can activate the 
innate immune system of the host when administered as described above (Hagan et al., 
2001). Other very effective adjuvants, usually only used for research purposes, are 
complete Freund’s adjuvant (CFA) and incomplete Freund’s Adjuvant (IFA). These 
represent a mixture of delivery, and immunostimulatory adjuvants. The mineral oil 
present in CFA forms antigen deposits at the injection site causing slow release or 
exposure to the immune system. The most active components of CFA are extracts of 
killed mycobacterium suspended in paraffin oil. This suspension is capable of very 
potently stimulating macrophages and ultimately induces a strong Th1 response in the 
immunized animal. The most immunostimulatory component of CFA is muramyl 
dipeptide (Roitt, 1994). The difference between CFA and IFA is that IFA does not 
contain the mycobacterial extracts. When using IFA, the antigen is usually suspended 
directly in paraffin oil prior to administering to the animal. Both adjuvants act as 
nonspecific stimulators of the immune cells thus enhancing humoral and cell mediated 
responses (Weeratna et al., 2000). Complications arising from the use of CFA due to its 
toxicity from causing necrosis or damage from over stimulation of macrophages within 
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the tissue at the inoculation site prohibits the use of CFA in humans (Kiyono and 
McGhee, 1996). 
 Different studies have reported the successful use of CpG-ODN as vaccine 
adjuvants. Most of these have been performed in mice and thus the extrapolation of these 
data into other vertebrates needs to be performed carefully. Another concern related to 
some of these reports centers on much of this research being done in vitro, which 
obviously does not take into consideration the multiple different effects that could alter 
the response in an in vivo system. Weeratna and his group compared different adjuvants, 
when given individually or mixed, and evaluated their ability to enhance an immune 
response against hepatitis B surface antigen (HBsAg). They also evaluated the degree of 
damage these antigens could cause when injected into the muscle tissue of the mice. 
They found that the combination of Alum and CpG had the best results for inducing 
measured immune responses with the smallest degree of tissue injury (Weeratna et al., 
2000). Another group demonstrated that intranasal immunization of mice against 
influenza virus simultaneously with CpG-ODN in a concentration of 50µl/mouse was 
effective to stimulate systemic and mucosal immune responses (Moldoveanu et al., 
1998). Another laboratory evaluated the mucosal response of CpG-ODN as mucosal 
adjuvants in mice, when immunized against one or more of the following antigens: 
Tetanus toxoid, HBsAg, and the vaccine Fluviral, alone or in combination. When 
evaluating three distinct routes of administration, oral, intranasal, and intra-rectal, their 
results indicated that CpG-ODN are capable of inducing antibody production in serum as 
well as in mucosa (McCluskie and Davis, 2000a; McCluskie et al, 2001b). This group 
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also observed that Non CpG-ODN induced an immune response by producing antigen-
specific IgG, as well as CpG or Ct (McCluskie and Davis,1999b; McCluskie et al, 
2000b, 2001c). 
 As stated above, most experiments performed to date investigating the 
immunostimulatory effects of CpG-ODN have been done in mice, primates, or humans. 
Until recently, there were only three studies that evaluated the effects of CpG-ODN as 
potential adjuvants in poultry. These included a study into the efficacy of CpG-ODN 
against IFA by comparing the efficacy in producing IgG and IgM after being injected 
subcutaneously with BSA in chickens. Observed results showed that the antibody levels 
were higher in the chickens injected with both CpG-ODN and BSA, suggesting a 
possible adjuvant effect via the subcutaneous route of administration (Vleugels et al., 
2002). A second study evaluated the proliferation of PBMC in peripheral blood in 6 
chickens with different sequences and backbones of CpG-ODN. Despite an obvious 
criticism of using such a limited number of experimental animals, the results of this 
experiment indicated that a sequence with 3 CPG motifs in the same ODN (sequence 
number 2135) was the most immunostimulatory (Rankin et al., 2001). Another study by  
Gomis and co-workers represents essentially the only complete report on a study done in 
vivo in chickens. They evaluated the administration route and the specific protection 
against E. coli infection induced by CpG-ODN when inoculated to birds via SC or IM 
administration (Gomis et al., 2003). Importantly, all studies investigating 
immunostimulatory properties of CpG-ODN that have been done in chickens to date 
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have not evaluated CpG-ODN as oral or mucosal adjuvants. Thus, exploration of CpG-
ODN to adjuvant mucosal immune responses is warranted using chickens as a model.  
Oral Immunization of Poultry 
 Bovine Serum Albumin (BSA), due to its broad-scale availability and ease of 
use, is a protein that has been frequently used in research settings to evaluate immune 
responses in mammals and chickens. Recently, it has been used as a food-protein antigen 
to assist researchers in understanding the phenomenon of oral tolerance in chickens, 
mice, and other mammals. 
 Oral tolerance is a condition of unresponsiveness of the immune system to an 
orally administered antigen (Miller and Cook, 1994). The avian immune system does 
become tolerant to orally ingested food antigens in a fashion similar to mammals, 
however, tolerance is usually only induced when the animal is a neonate, usually during 
the first week of life (3- 10 days post hatch). Following this time, fed antigens become 
immunostimulatory, and do not induce tolerance. Interestingly, this phenomenon 
occurring at 10 days of age in the chicken coincides with the appearance of the Peyer’s 
patches (PP), more extensive B and T cell colonization, and subsequent cytokine 
expression at mucosal sites, all of which are required for the induction of humoral 
responses in the mucosa (Miller and Cook, 1994, Ameiss et al., 2004, Klipper et al., 
2004). The ability of an orally administered antigen to either induce tolerance or 
immunity depends not only on the age of the animal, but on the frequency, dose and 
physical presentation of the antigen given. It has been shown that soluble antigen given 
orally in low concentrations on consecutive days of administration (Ameiss et al., 2004) 
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induces a robust systemic and local antibody response. When administered in similar 
fashion in terms of concentration and route of administration, but using a dry or dry or 
pelletized form of antigen, tolerance is induced (Klipper et al., 2000, 2001). Thus, after 
the birds become more immunologically mature, the ability of developing oral tolerance 
to soluble antigens is lost. According to Ameiss et al., (2004) drinking water 
administration is effective in eliciting a humoral response than a direct oral gavage, and 
equally as good as intra-peritoneal antigen administration with adjuvant in Leghorn 
chickens. Klipper and co-workers demonstrated that the hyper immunization of breeding 
hens with BSA and the subsequent presence of maternal antigen-specific antibodies in 
progeny inhibits tolerance. These authors suggest this to be mechanisms to describe why 
some pathogens which are exposed to the neonatal chick do not induce tolerance 
(Klipper et al., 2004). 
Poultry Salmonellosis 
According to the Food-borne Diseases Active Surveillance Network (FoodNet), 
in their final report for 2001; the bacterial pathogens with the highest relative incidence 
for causing bacterial food borne illness in humans during the period between 1996 and 
2001 were Campylobacter, Salmonella, and Shigella. Even though there was a decline of 
Salmonella incidence for food-borne disease during the period of 1996 through 1999; the 
increase in the incidence of infections caused by Salmonella in 2000 and 2001 represents 
an emerging challenge to public health agencies. According to the CDC (CDC, 2004), 
human salmonellosis constituted 31 % of the food-related deaths in the United States 
between 1992 and 1997 (Mead et al., 2004). 
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Salmonella are gram negative, aerobic, non-capsulated, and non-sporulating 
bacteria, which can infect mammals, birds, reptiles, and amphibian hosts (Gast, 2003). 
Salmonella are widely distributed in nature. They have been a great concern for the 
poultry and animal agriculture industries for quite some time. Two host specific, non 
motile strains of Salmonella, S. pullorum and S. gallinarum which cause Pullorum 
Disease and Fowl Typhoid, respectively, have been adequately controlled in most parts 
of the world and essentially eradicated from commercial flocks within the U.S., Canada, 
Australia, Japan, and Western Europe. At least within the U.S., no outbreaks have been 
reported since 1980 (Gast, 2003).  
Of the 2400 different serotypes of Salmonella which exist, only a small fraction 
of these serotypes are known to be linked to both poultry reservoirs and human health. 
Infection in humans usually occurs when contaminated products including eggs, or raw 
/undercooked meat are consumed (Charlton et al., 2000). To reduce human food-borne 
salmonellosis traced back to poultry as the source of infection, the poultry industry and 
many research laboratories are constantly exploring new methodologies that will help 
decrease Salmonella incidence in poultry. Poultry producers and processors must also 
comply with mandatory regulations imposed by federal regulatory agencies to keep the 
presence of Salmonella on processed poultry or poultry products to a minimum accepted 
standard. 
Most serotypes of Salmonella enterica subspecies enterica responsible for 
gastrointestinal disease among humans are commonly grouped as paratyphoid (PT) 
Salmonellae. They consist of serotypes that include S. enteritidis, S. oranienberg, S. 
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montevideo, S. newport, S. typhimurium, S. anatum, S. derby, and S. bredeney. Of these, 
S. enteritidis, S. typhimurium, and S. montevideo are frequently isolated in poultry 
(Charlton et al., 2000).  
In humans, gastroenteritis is the most common clinical sign of an infection by 
paratyphoid Salmonellae. Human salmonellosis can also manifest vomiting, diarrhea, 
fever, other systemic symptoms, or even death (Buck and Weker, 1998). Chickens 
infected with S. enteritidis and S. typhimurium, present minimal, if any clinical signs. 
However, when affected, chickens are usually 2 days old or less and often suffer high 
mortality related to systemic disease (Beal et al., 2004). Other reports mention no 
mortality, but instead a large shedding of bacteria through feces due to massive bacterial 
replication in the gut (Zhang-Barber et al., 1999). Regardless of the presence or absence 
of clinical signs in young or mature chickens, these paratyphoid serotypes can colonize 
the chicken oviduct, ceca, and other regions of the gastrointestinal tract, and are often 
isolated from internal organs such as liver and/or spleen which can be primary sites of 
replication along with the ceca (Gast, 2003). This extensive degree of colonization or 
infection in commercial poultry underscores the possible threat to human health 
associated with these bacteria. Transmission of PT Salmonellae to other poultry can 
occur through shedding of the bacteria in feces, within a hatchery from the presence of 
contaminated egg shells, through vectors such as personnel, birds, rats, insects, or 
through fomites like farm equipment (Gast, 2003). 
Salmonella are intracellular facultative organisms. Depending on the infectious 
dose, age, and health condition of the animal, the development of the disease will result 
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either in gut colonization, invasion of different organs, or death. There are different 
possible routes of inoculation consisting of: oral, intra-tracheal, conjunctiva, intra-
cloacal, aerosol, or through contaminated semen (Gast, 2003). 
Salmonella spp are capable of inducing both systemic and mucosal antibody 
production in poultry. Serum antibodies, mainly the IgG isotype, have been reported to 
interfere with bacterial adherence to mucosal surfaces (Gallin and Fauci, 1985). Several 
distinct approaches in vaccine development which target the elicitation of a humoral 
response to Salmonella in poultry have been taken to date. Live, attenuated, and killed 
bacterins have all been shown to be effective in some respects, but often inconsistent. 
One of the most common approaches to the vaccination of commercial poultry against 
Salmonella through the years has involved the use of an oil-immersion bacterin. Two 
reports by Gast and co-workers evaluated the ability of two killed S. enteritidis bacterins, 
one acetone killed and one commercially available, administered orally or 
subcutaneously to laying hens. The ability to reduce intestinal colonization and shedding 
in the feces was evaluated. In these experiments bacterins only resulted in partial 
protection to hens vaccinated by either oral or subcutaneous routes (Gast et al., 1992, 
1993). Limited protection from the use of bacterins has resulted in other researchers 
developing modified live, or gene deletion vaccines. Studies with genetically modified 
Salmonella strains have also been reported and modification of both virulent and 
avirulent strains has been shown to induce humoral responses in chickens on a dose 
dependent basis (Curtiss III et al., 1993). Curtiss and co-workers claim that using a live, 
avirulent Salmonella typhimurium vaccine strain can diminish colonization, shedding, 
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and result in progeny protection through transovarian antibody transmission against a 
number of different Salmonella serotypes (Curtiss III et al., 1993; Curtiss III and 
Hassan, 1996; Hassan et al., 1993, 1997; Hassan and Curtiss III, 1994). After 
immunization with this modified strain, good IgG levels are present in egg yolk, serum, 
and intestinal secretions of the neonatal chickens. Also, the immunization of different 
animals with this same Salmonella modified strain, is observed to produce a good 
mucosal, humoral and cellular immune response, against LPS, and outer membrane 
proteins (OMP; Curtiss III and Hassan, 1996). Many additional reports indicate an 
incremental increase antibody levels, mainly IgG and IgA in bile, intestinal mucosa, and 
serum occurs after oral immunization (Beal et al., 2004). The knowledge of humoral 
kinetics in poultry is still not well understood, however, leading Zhang-Barber et al. 
(1999) to describe the development of new and effective vaccines as an empirical 
challenge.  
While precisely unknown to what extent they may play at present, humoral 
responses may be an important component in the chicken immune response to overcome 
Salmonella colonization. The need to reduce the incidence of Salmonella in poultry is 
imperative; therefore there is still a need for developing improved and more successful 
strategies for vaccination. Successful vaccination that will bring better protective 
immunity to limit the invasiveness of the bacteria and reduce its multiplication in 
affected tissues is clearly needed.  
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Eimeria Infections in Commercial Poultry 
Coccidiosis is an enteric parasitism infection of great economic importance in 
commercial poultry. Some estimates describe costs and losses to the U.S. poultry 
industry between 1 to 2 billion dollars annually (Yun et al., 2000, Morris et al. 2004). 
Economic losses associated with this enteric disease condition are not only due to 
morbidity / mortality or decreases in performance, but also to costs associated with 
constant medication that must be given to essentially all floor-reared commercial poultry 
flocks for the duration of the productive cycle. The emergence of drug resistance in 
strains of coccidia, and the pressure applied to the industry to restrict the use of 
antibiotics or medications in products consumed by humans, is forcing researchers to 
evaluate and investigate alternative methods of control.  
Coccidia parasites belong to the genus Eimeria, member of the family Eimeriidae 
that belongs to the subphylum Apicomplexa. There are seven species of Eimeria that 
affect chickens: E. acervulina, E. brunetti, E. maxima, E. mitis, E. necatrix, E. praecox, 
and E. tenella. The most common species usually found within broiler production are 
Eimeria acervulina, E. maxima, E. mitis, and E. tenella (Crouch et al., 2003). Each 
species can parasitize the intestine of commercial poultry individually or in combination. 
However, the Eimeria that infect poultry are host specific and show a definitive tissue 
tropism within the area of the gut they choose to invade. The morphology (size, shape, 
and color) of oocysts also varies among species, as well as the kind of macroscopic 
lesion they produce which facilitates species specific differential diagnosis (McDougald, 
2003). 
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Oocysts shed through feces sporulate in the environment making them infective 
when ingested by other poultry. After such ingestion, the sporozoites are released from 
sporocyst and oocyst shells within the gizzard, and are then able to invade and establish 
in the intestinal mucosa or the lamina propria of the gut. Within these sites, sporozoites 
undergo multiplication until the liberation of schizonts, the most pathogenic phase of the 
protozoan. Within enterocytes, they multiply sexually, resulting in zygotes which mature 
into oocysts. Following two stages of sexual development, formed oocysts are liberated 
from host cells and release into the lumen for excretion to the environment. Oocysts are 
excreted for several days by this manner through the feces (Yun et al., 2000). Although 
it depends on the species, the entire life cycle usually takes from 4 to 6 days to complete 
(McDougald, 2003).  
Eimeria spp. can affect essentially all regions of the both the small and large 
intestine of commercial poultry with species specificity (Yun et al., 2000; McDougald, 
2003). Infection with coccidia can result in increased mucus secretion, cellular rupture, 
reduced nutrient absorption, hemorrhage, diarrhea, dehydration, weight loss, and 
occasionally death. Egg production in laying hens can also decrease with coccidiosis 
(Yun et al., 2000). The kind of lesions formed in the intestine as a result of infection can 
predispose for the establishment of other enteric pathogens, including Clostridium 
perfringens or Salmonella typhimurium (Gast, 2003; McDougald, 2003). In chickens the 
most common Eimeria to invade the upper small intestine or duodenum is E. acervulina. 
E. maxima, normally infects the lower duodenum, jejunum, and ileum. Whereas, E. 
tenella typically infects the cecum (McDougald, 2003). Long term survival of oocysts in 
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rearing environments requires certain environmental characteristics in order to survive 
and be viable; including high rearing density, low ammonia, higher levels of oxygen, 
and susceptible chickens (Chapman et al., 2002).  
Eimeria is highly immunogenic, but does not demonstrate cross-species 
protection, thus requiring vaccines to include all the endemic strains and species present 
in a particular poultry production complex. Since they are immunogenic, they have the 
capacity of enhancing a protective immunity for a long period of time after 
immunization; but some species require variable numbers of oocysts to induce such 
immunity. The exact mechanism of the humoral response in coccidia infection is still not 
well understood. Some studies report that the presence of antibodies inhibits sporozoite 
invasion by eliminating and destroying them within the lumen (Rose et al., 1984; 1987). 
It is also known that the infection with Eimeria will induce parasite-specific antibody 
production locally and systemically (Lillehoj and Trout, 1996). It has been demonstrated 
with different approaches that the participation of T cells in responses against coccidia is 
of major importance (Lillehoj and Trout, 1996). There is an inverse proportion between 
presence of T cells and susceptibility of the chick to Eimeria infection. Whenever there 
is a decrease in T cells, resulting in a measurable decrease in IFNγ and IL2, there is a 
corresponding increase in susceptibility to Eimeria (Lillehoj et al., 2004). 
Lymphoproliferation assays have been very useful in helping to determine the 
importance of the activation of antigen specific T cells from chicken immunized with 
Eimeria. There are also differences in the T-cell population in the duodenum after 
primary and secondary immunization (Lillehoj and Trout, 1996). For example, after the 
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secondary infection, an important number of CD8+ IEL cells increases, higher than in 
the primary infection, and a reduced oocyst production is apparent. CD4+ IEL cells also 
increase 7 days post primary infection. Overall, there is a close relation between infected 
epithelial cells and the presence of this CTL cells in the gut. Hens immunized with 
gametocyte surface antigens of E. maxima are able to produce specific IgG antibodies 
and transfer them to their progeny (Lillehoj et al., 2004). Lillehoj and Trout (1996) 
demonstrated in various studies that within the IEL, CD8+ cells are actually involved in 
transporting sporozoites from villus enterocytes to crypt enterocytes where establishment 
and completion of the life cycle would continue. These experiments revealed that when 
depleting CD8+ cells from a chicken, the oocyst production decreased to 55 % in the 
primary infection with E. tenella and E. acervulina (Lillehoj and Trout, 1996). 
Newcastle Disease Virus 
 Newcastle Disease (NDV) is a permanent threat to the aviculturists and the 
commercial poultry industry in the United States and worldwide. According to the OIE 
(Office of International Epizootics) NDV is a disease on list A having the following 
characteristics: “a transmissible disease that has the potential for very serious and rapid 
spread, irrespective of national borders, that is of serious socio-economic or public 
health consequence, and that is of major importance in the international trade of animals 
and animal products.” During the last few years, a total of 2618 confirmed outbreaks 
with exotic NDV (END) have been reported in the U.S., including outbreaks in the states 
of California, Nevada, Arizona, and Texas. In previous decade, especially during 1995, 
1997, and 1998, there were additional outbreaks with NDV, however in most cases, with 
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a less virulent serotype. The economic impact of NDV outbreaks is characterized by 
high mortality in END infections in commercial flocks, condemnation and eradication of 
other infected flocks, and trade restrictions associated with quarantine and surveillance 
of affected areas within individual states where outbreaks have been detected.  
NDV is a Paramyxovirus that belongs to the family Paramyxoviridae and its 
genus is Rubulavirus. It exists as one serotype, giving it the name Avian Paramyxovirus 
type 1 (APMV-1) (Alexander., 2003). NDV consists of an enveloped, single molecule 
with single stranded RNA. Its genome encodes for six different proteins, and an RNA 
directed RNA polymerase. The most important of these proteins, in terms of diagnosis 
and virulence factors, are hemagglutinin and neuraminidase proteins (HN), and the 
fusion protein (F). HN is the responsible for hemagglutination of avian red blood cells 
(RBC), and is the antigenic structure of the virus. The fusion protein fuses with host cell 
receptors giving rise to virus replication. Both play a major role, as surface proteins, by 
inducing an immune response in the host (Alexander, 2003). 
 NDV infection begins with attachment to host cell receptors through the HN 
protein. The two membranes fuse by the action of the F protein which causes entrance of 
the virus into the cell. Within the cytoplasm the virus replicates. The RNA directed RNA 
polymerase transcribes a complementary transcript of positive sense of its own genome 
that will work as an mRNA helping the translation of its own proteins utilizing the hosts’ 
cells. During its replication, NDV proteins are produced with the F protein, which is a 
precursor (F0) that has to be cleaved to F1 and F2 in order to be virulent. If no cleavage 
occurs, the result will be proteins with no virulence. The cleavage is determined by host 
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protease sensitivity to the amino acid sequence of the virulent strain. The amino acid 
sequence varies depending on the strain of virus. Virulent strains for example, present 
arginine and phenylalanine in specific locations of the amino acid sequence, while non-
virulent strains present different sequences (Alexander, 2003). 
Transmission among poultry can occur by ingestion or inhalation of infected 
secretions or contaminated feces. The transport or movement of people, equipment, feed, 
water, birds, or even vaccines from an endemic area into a “clean”zone is also known to 
result in infection. The incubation period of NDV varies form 2 to 15 days in poultry 
(Alexander, 2003). 
Historically, the only effective means of controlling NDV has been through 
vaccination. The most common routes of inoculation of a vaccine to protect against 
NDV are oral, ocular, and intranasal. The humoral immune response to vaccination is 
first observed within 6-10 days post immunization where antibody production in the 
mucosa and serum is evident. IgM, IgG, and IgA have been observed in serum and tears 
after ocular immunization with the B1 strain of NDV, a mildly virulent strain live virus 
vaccine (Al Garib., et al., 2003). It is well proven, that the ocular (eye drop) 
administration of a vaccine can induce antibody production at mucosal surfaces and in 
serum to neutralize the virus and prevent infection. The Hitchner B1 strain of NDV is 
also commonly used as a vaccine strain. Some reports suggest that the eye drop 
application of this vaccine similarly enhances IgM, IgA, and IgG production in serum 
and tears. Such elevated systemic and local antibody titers have been correlated with 
enhancing the protection against this pathogen (Russell and Ezeifeka, 1995). Overall, 
   
39
vaccination protects flocks by diminishing the clinical signs that the virus produces 
within the host. Depending on the vaccine strain used however, replication and shedding 
of the virus may not be completely eliminated (Russell and Koch, 1993). While 
successful in many respects, the observation of vaccinated animals continuing to be 
susceptible to NDV suggests improvements in vaccines and methods of administration 
are still needed. Presently, researchers are in constant search for vaccines that will 
provide greater protection and improve animal health for aviculturists and the 
commercial poultry industry 
Summary and Conclusions 
 A major research interest in our laboratory at present is investigating vaccine 
efficacy to improve enteric and respiratory disease resistance in commercial poultry by 
studying host immune responsiveness to vaccination and challenge. As such, the overall 
objective of the present investigation was to investigate the potential of CpG-ODN to act 
as an oral or mucosal adjuvant when administered to broilers and leghorns immunized 
with commercially available NDV, coccidial, or Salmonella vaccines, or BSA when 
administered by mucosal routes of immunization.  
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CHAPTER III 
 
EFFECTS OF CPG OLIGODEOXYNUCLEOTIDES ON VACCINATION OR 
IMMUNIZATION STRATEGIES DIRECTED AGAINST NEWCASTLE 
DISEASE VIRUS, EIMERIA, SALMONELLA, OR BOVINE SERUM ALBUMIN 
(BSA) IN COMMERCIAL STRAIN CHICKENS 
 
Introduction 
 Newcastle Disease virus (NDV) is a permanent threat to aviculturists and the 
commercial poultry industry in the United States and worldwide. According to the OIE 
(Office of International Epizootics) NDV is a disease on list A with the following 
characteristics: “a transmissible disease that has the potential for very serious and rapid 
spread, irrespective of national borders, that is of serious socio-economic or public 
health consequence, and that is of major importance in the international trade of animals 
and animal products.” During the last few years, a total of 2618 confirmed outbreaks 
with exotic NDV (END) have been reported in the U.S., throughout the states of 
California, Nevada, Arizona, and Texas. In previous decade, especially during 1995, 
1997, and 1998, there were additional outbreaks with NDV, however in most cases, with 
a less virulent serotype. The economic impact of NDV outbreaks is characterized by 
high mortality in END infections in commercial flocks, condemnation and eradication of 
other infected flocks, and trade restrictions associated with quarantine and surveillance 
of affected areas within individual states where outbreaks have been detected. 
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Coccidiosis is an enteric parasitic infection of great economic importance in commercial 
poultry. Some estimates describe costs and losses to the U.S. poultry industry that are 
between 1 to 2 billion dollars annually (Yun et al., 2000, Morris et al. 2004). Economic 
losses associated with this enteric disease condition are not only due to morbidity / 
mortality or decreases in performance, but also to costs associated with constant 
medication that must be given to essentially all floor-reared commercial poultry flocks 
for the duration of the productive cycle. The emergence of drug resistant coccidia, and 
the pressure applied to the industry to restrict the use of antibiotics or medications to 
products consumed by humans, is forcing researchers to evaluate and investigate 
alternative control methods of control.  
According to the Food-borne Diseases Active Surveillance Network (FoodNet) 
final report in 2001; the bacterial pathogens with the highest relative incidence for 
causing bacterial food borne illness in humans during the period between 1996 and 2001 
were Campylobacter, Salmonella, and Shigella. Even though there was a decline of 
Salmonella incidence for food-borne disease during the period of 1996 through 1999; the 
increase in the incidence of infections caused by Salmonella in 2000 and 2001 represents 
an emerging challenge to public health agencies. According to the CDC (CDC, 2004), 
human salmonellosis constituted 31 % of the food-related deaths in the United States 
between 1992 and 1997 (Mead et al., 2004). Poultry and poultry products are frequently 
implicated as sources of human foodborne salmonellosis. 
A common strategy for controlling or minimizing the presence of each of these 
pathogens in commercial poultry flocks is vaccination. The commercial poultry industry 
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relies heavily vaccines to protect chickens and turkeys against pathogens that threaten 
poultry health and the subsequent overall economics of the industry. The fundamental 
task of the immune system in responding to vaccination is to generate protection in the 
host against invading microorganisms or pathogens through a cooperative approach 
involving both innate and adaptive immunity. Innate immune responses are typically 
activated by innate system cells, such as macrophages, heterophils, or dendritic cells, 
which then act in concert to either kill the invading microbe or augment and trigger an 
appropriate adaptive immune response. Because innate immune cells lack the highly 
specific antigen receptors found on T and B cells they often rely on surface membrane 
proteins known as pattern recognition receptors (PRRs). PRRs have the ability to detect 
surface components of microbial pathogens known as pathogen associated molecular 
patterns (PAMPs). PAMPs recognition by PRRs in this setting is an indication of a threat 
to the host in the form of potential infection. Such recognition activates appropriate 
defense pathways in the innate system to either remove the pathogen or stimulate the 
adaptive system to act upon the pathogen for its ultimate removal.  
CpG motifs naturally present in bacterial DNA represent one of the most recent 
examples of substances that influence adaptive immune responses by activating the 
innate immune system. CpGs are 6-8 base nucleotide motifs consisting of an 
unmethylated CpG dinucleotide that induce cells of the innate immune system to 
increase phagocytosis, pro-inflammatory cytokine production, activation of NK cells, 
increase nitric oxide generation by macrophages, and stimulate B cell proliferation and 
differentiation. The ability of CpG-ODN to act as vaccine adjuvants has been explored 
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extensively in recent years in mammals, but very little research has been conducted 
along these lines in commercial poultry. In recent years, DNA vaccines or DNA extracts 
from bacteria have been recognized as having tremendous potential for improving 
vaccination strategies in commercial poultry against different pathogens. The objective 
of this investigation was to evaluate the administration of CpG-ODN as a potential oral 
adjuvant to commercially available vaccines against Salmonella, Eimeria spp., and 
Newcastle Disease Virus, and a common protein antigen, bovine serum albumin (BSA). 
Measured experimental outcomes included the level of antibodies produced and 
protection against subsequent clinical challenge in experimental animals following 
immunization and vaccination procedures evaluated in this study. 
Materials and Methods 
Experimental Animals 
For experiment 1, which consisted of 3 replicate trials of 160 chickens each, 
fertile eggs from specific pathogen free breeder flocks were obtained from Charles River 
SPAFAS (SPAFAS Avian Products and Services, North Franklin, CT.), incubated, and 
hatched at the Texas A&M University Poultry Science Center. For experiment 2, 160 
straight-run (Cobb X Cobb) broiler chicks were obtained from a local commercial 
hatchery on day-of-hatch. For experiments 3 (n=252) and 4 (n=132), single-comb-white-
leghorn (SCWL) (Hy-Line W-36) chicks were obtained from a local commercial 
hatchery on day-of-hatch. Additionally in experiment 4, 132 straight-run (Cobb X Cobb) 
broiler chicks were obtained on day-of-hatch from the same hatchery used to obtain 
chicks for experiment 2. At the time of chick placement in all experiments, chicks were 
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provided ad libitum access to drinking water and a balanced, un-medicated, corn-
soybean ration that met or exceeded National Research Council (NRC, 1994) guidelines 
for poultry. Chicks were wing banded, randomly assigned to specific experimental 
groups, and placed on either floor pens with clean pine shavings (experiments 1, 3, and 
4), or wire starter batteries (experiment 2) with age-appropriate supplemental heat. 
Vaccines and BSA 
 The vaccines for NDV, Coccidia, and Salmonella were obtained from the 
individual vaccine manufacturers for use in the present experiments. The vaccine used 
for NDV vaccination strategies was live virus B1 Strain, titer 107.5 obtained from Merial 
Select (Gainesville, GA). The live oocyst coccidial vaccine used in experiment 2 was 
Coccivac®-B obtained from Schering-Plough Animal Health (Millsboro, DE). This 
vaccine contained four species of Eimeria (E. tenella, E. maxima, E. acervulina, E. 
mivati). In experiment 3, chickens were vaccinated with the modified live (deletion 
mutant) Salmonella vaccine Megan® Vac 1 manufactured by Lohmann Animal Health 
International (Gainesville, GA) for Megan Health, Inc (St. Louis, MO). Immunization of 
chickens in experiment 4 was performed with BSA-fraction V obtained from Sigma 
Chemical Company (St. Louis, MO). 
CpG-ODN and Non CpG-ODN 
In all experiments, either synthetic CpG-ODN or Non CpG-ODN were evaluated 
as oral or mucosal adjuvants respective to experimental group. The CpG-ODN that was 
used was the ODN 2007 (5’ TCG TCG TTG TCG TTT TGT CGT 3’; CpG motifs are 
underlined) as previously described (Rankin et al., 2001). As a control to the use of 
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CpG-ODN, we also used Non CpG-ODN 2041 (5’CTG GTC TTT CTG GTT TTT TTC 
TGG 3’) also as described previously (Rankin et al., 2001). The CpG-ODN and the Non 
CpG-ODN were synthesized with a phosphorothioate backbone to increase resistance to 
hosts nucleases. Both ODN were obtained from Integrated DNA Technologies, Inc. 
(Coralville, IA). Both ODN were resuspended in sterile pyrogen-free PBS immediately 
prior to administration. Each bird receiving CpG-ODN or Non CpG-ODN was 
administered a dose of 50µg through the specific route of administration (oral or 
intranasal) relative to experiment and experimental group. 
Indirect Enzyme Linked Immunosorbent Assay (ELISA) 
 In experiment 1, a commercial ELISA kit (Idexx Laboratories, Inc., Westbrook, 
ME) was used to evaluate the specific NDV IgG levels in serum samples obtained from 
experimental animals. For experiments 2, 3, and 4, indirect ELISA was performed on all 
serum samples using flat-bottomed 96 well plates (Nalge Nunc International, Rochester, 
NY). Prior to addition of sample antiserum, plates were coated with antigen and allowed 
to incubate overnight. Respective to individual experiment, this consisted of adding the 
following to each well: 5.2 µl of recombinant protein of E. acervulina (EASZ240) per 
well for experiment 2, 10µl of LPS specific for S. enteritidis (Sigma L6011) or S. 
typhimurium (Sigma L6511) per well during experiment 3, or 5µl of BSA fraction V 
(Sigma 2960) per well during experiment 4. Following antigen binding, each well was 
rinsed with PBS-T and then blocked with a blocking buffer containing 0.5% of BSA for 
half an hour. Plates were rinsed again and then 150µl of diluted serum was added into 
each well. Serum dilutions for all experiments ranged between 1:320 to 1:2560 per 
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sample. Data presented represent serum dilutions of 1:640. All the dilutions were 
performed within each plate. Following sample addition to wells, plates were agitated 
for 2 hours. Following rinsing, 150µl of horseradish peroxidase (HRPO) conjugated goat 
anti-chicken IgG (dilution 1:10,000) was added to each well in experiments 2 and 4. In 
experiment 3, a conjugated rabbit anti-Chicken IgG (Sigma A9046) was used. For all the 
samples in all experiments, a rabbit conjugated anti-Chicken IgG (Sigma A 9046) was 
used at the same dilution (1:10,000). Plates were incubated for two hours, rinsed again, 
and then a substrate solution containing 100µl of DMSO with 1mg TMB in 10ml of 
sodium acetate buffer (pH 5.5) was added to all wells. Reactions were stopped after 15 
min by adding 50 µl of 1M sulfuric acid. Plates were read in Magellan multi well plate 
reader at a wavelength of 450nm. Plates were read in the Magellan multi-well plate 
reader at a wavelength of 620 nm, according to specification of the own kit. 
Experimental Design 
 Experiment 1. To evaluate the ability of CpG-ODN to adjuvant NDV vaccination 
on day-of-hatch ,all chicks were randomly separated into the following eight groups: 1) 
Vaccine alone (V), 2) Vaccine alone with boost on day 14 (V 1& 14), 3) Vaccine + 
CpG-ODN (V + CpG), 4) Vaccine + CpG-ODN with boost on day 14 (V + CpG 1 & 
14), 5) Vaccine + Non CpG-ODN (V + Non CpG), 6) Vaccine + NON CpG-ODN with 
boost on day 14 (V + Non CpG 1 & 14), 7) challenge control and 8) negative control. 
CpG-ODN or Non CpG-ODN were co-administered with the vaccine (live virus Type 
B1 Strain titer 107.5 from Merial Labs) intranasally and intraocularly to chicks respective 
to experimental groups. 14 days later, a booster administration of vaccine, vaccine + 
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CpG ODN, or vaccine + Non-CpG ODN was given respective to group. On day 28, 
chickens from all experimental groups, except negative control group, were challenged 
intranasally and intraocularly respective to experimental groups with a Newcastle 
Disease Virus La Sota Field strain at a dose of 109.2. To evaluate antibody levels by 
ELISA, an approximate 1 ml sample of blood was obtained by jugular or bicipital vein 
venipuncture and allowed to clot for serum collection. Serum was transferred to clean 
micro centrifuge tubes, and frozen at -20 C until assay by ELISA. Samples were taken 
on days 14, 28, and 31 post-vaccination of each replicate experiment.     
 Experiment 2. To evaluate the potential adjuvant properties of CpG-ODN during 
coccidial vaccination, 160 day-of-hatch broiler chicks were obtained and randomly 
distributed into 4 different experimental groups of 40 birds each. Chicks were reared on 
wire in an electrically heated brooder battery unit with one experimental group per level. 
Specific experimental groups consisted of: 1) non-vaccinated control, 2) Vaccinated, 3) 
Vaccinated with CpG-ODN, and 4) Vaccinated with Non CpG-ODN. Vaccination was 
performed on one day post-hatch by oral co-administration of CpG-ODN (50µg/bird) or 
Non CpG-ODN (50µg/bird) and one manufacturer’s recommended dose of Coccivac® B. 
On day 21 all chickens were weighed, transferred to two grower battery units, and 
further separated into eight experimental groups of 20 birds each for clinical challenge 
with E. acervulina or E. tenella. The heterologous mixed challenge on day 21 consisted 
of 5x105 oocysts/bird of E. acervulina and 1 x105 oocysts/bird of E. tenella was 
administered per os to chickens respective to experimental group. Day 6 post-challenge, 
all experimental animals were bled, weighed, and then killed for lesion score 
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determination according to the methods of Johnson and Reid (1970). Additionally, to 
determine antibody levels resulting from coccidial vaccination and challenge, blood was 
taken on days 10, 21, and 27 in similar fashion to the above description for obtaining and 
processing blood samples for experiment 1.  
 Experiment 3. To evaluate the ability of CpG-ODN to adjuvant vaccination 
strategies against Salmonella, day-of-hatch 252 SCWL chicks were randomly separated 
into 7 experimental groups. These groups consisted of: 1) Vaccine alone, 2) Vaccine 
alone with boost on day 14, 3) Vaccine + CpG-ODN, 4) Vaccine + CpG-ODN with 
boost on day 14, 5) Vaccine + Non CpG-ODN, 6) Vaccine + Non CpG-ODN with boost 
on day 14, and 7) negative control. CpG-ODN or Non-CpG ODN were orally co-
administered with the S. typhimurium deletion mutant vaccine Megan® Vac 1 on day-of-
hatch. A booster immunization with the same vaccine, vaccine + CpG ODN, or vaccine 
+ NON-CpG ODN, was administered respective to experimental group on day 14. On 
day 28, chickens from all experimental groups were separated and mixed into three 
separate groups, consisting of a non-challenged group, and individual S. enteritidis or S. 
typhimurium challenged groups. Field strain challenge of experimental animals with 
Salmonella enteritidis and Salmonella typhimurium was performed by giving an oral 
dose of 5 X 108 cfu/ml to each chicken. All birds were bled for antibody level 
determination following vaccination and challenge, as described above, on days 14, 28, 
and 35 post-vaccination. 
 On day 35, seven days post-Salmonella challenge, all challenged animals were 
killed and liver, spleen, and ceca were enriched in tetrathionate broth for 24 h at 42 C for 
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specific recovery of either S. typhimurium or S. enteritidis. Additionally, the cecal 
contents from 5 birds per group were serially diluted (10-1, 10-2, 10-3, 10-4 dilutions in 
Butterfield’s solution) and plated for direct enumeration of both challenge isolates. All 
samples were plated to brilliant green agar containing 20 µg/ml nalidixic acid and 25 
µg/ml sodium novobiocin. All plates were incubated at 37 C for approximately 24 h and 
all suspect colonies were confirmed both biochemically and serologically.  
 Experiment 4. For this experiment, designed to simultaneously evaluate the 
efficacy of CpG-ODN in elevating antigen specific antibodies to BSA in both broiler and 
SCWL chickens, day-of-hatch chicks were randomly separated into the following six 6 
different experimental groups: 1) BSA alone, 2) BSA + CpG (50 µg/chick), 3) BSA + 
CpG (75µg/chick), 4) BSA + Non CpG (50 µg/chick), 5) BSA + Non CpG (75 
µg/chick), or 6) Negative control. Broiler and SCWL chicks were reared separately 
throughout the experiment. All birds designated for BSA immunization received ad 
libitum access to bell drinkers with water containing 1.4mg/ml of BSA on day 15 
through day 21. On the first day of immunization, each animal respective to 
experimental group also received either 50 or 75 µg CpG-ODN or Non CpG-ODN along 
with 25 mg of BSA orally using a feeding needle. Chickens in negative control groups 
were provided bell drinkers with tap water only. All animals, except the experimental 
animals in the control groups, also received a BSA booster immunization without CpG-
ODN or Non CpG-ODN on day 26 following the last day of drinking water 
immunization. The boost consisted of 24 hours access to bell drinkers containing a 
solution of 1.4mg/ml of BSA. Blood samples for antibody level determination were 
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taken and processed, as described above, on days 19 and 33 post final day of 
immunization. 
Statistical Analysis 
Serum samples form all experiments were read in duplicate and normalized for 
plate effects by dividing by a positive standard. The mean absorbance of serum samples 
were analyzed using the General Linear Model of analysis of variance (ANOVA) and 
statistically different means (p<0.05) were further separated using Duncan’s Multiple 
Range Test. All analyses were performed using SPSS software (SPSS, v. 11.0, 2001). 
Differences in the log10 CFU value of S. typhimurium and S. enteritidis in the cecal 
contents were evaluated in the same way. 
Results 
Experiment 1. 
Experiment 1, which evaluated the effectiveness of CpG-ODN to adjuvant 
vaccination of commercial SPF chickens with a commercially obtained NDV vaccine, 
consisted of 3 replicate trials conducted over time. In the first replicate trial, on day 28, 
animals in the Vaccine + CpG 1& 14 experimental group were observed to have the 
highest (p<0.05) anti-NDV IgG levels, which were elevated above levels in animals 
from all other experimental groups. The Vaccine + CpG-ODN, Vaccine + Non CpG-
ODN, and Vaccine + Non CpG-ODN were significantly different (p<0.05) from vaccine 
alone, vaccine 1&14, and the challenge control (control 1) and negative control (control 
2) groups. Further, vaccine alone and vaccine 1&14 were significantly different from the 
negative and challenge controls. On day 31, Vaccine + Non CpG 1&14 remained higher 
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and was markedly (p<0.05) different from Vaccine alone, Vaccine 1&14, Vaccine + 
CpG-ODN 1&14, negative and challenge control groups, but were not different from 
groups Vaccine + CpG-ODN and Vaccine + Non CpG-ODN (Table 1). Antibody levels 
in animals in the Vaccine + Non CpG-ODN experimental group were higher (p<0.05) 
than levels in animals from vaccine alone and the negative and challenge controls. 
Further, we observed that Vaccine 1&14, Vaccine + CpG, Vaccine + CpG 1&14, 
vaccine + Non CpG do not differ among themselves, but showed an elevation when 
compared with the negative and control experimental groups. These levels were not 
significantly different from the Vaccine alone group however.  
 For the second replicate trial, there were a few modifications to the experimental 
design as compared to replicate 1. Of these, two additional groups were added: a 
Vaccine + CpG on day-of-hatch group that received a boost of only CpG-ODN 
(administered in a PBS solution, through ocular and intranasal routes of administration) 
on day 14. A similar grouped that was added took the same approach but with only Non 
CpG-ODN only on day 14. In this replicate, an extra time point for blood collection, day 
14, was also added. Results from day 14 bleedings during this trial revealed that the 
animals in the experimental group Vaccine + Non CpG-ODN 1& Non CpG-ODN 14 had 
the highest (p<0.05) antibody levels among all experimental groups, however these 
levels were not significantly different from Vaccine alone, vaccine + CpG-ODN, 
Vaccine + CpG-ODN 1&14, and Vaccine + Non CpG-ODN 1&14 (Table 1). Animals in 
the groups Vaccine alone, Vaccine + CpG-ODN, Vaccine + CpG-ODN 1&14 and 
Vaccine + Non CpG-ODN 1&14, were not significantly different among themselves, but 
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were different (p<0.05) when compared against Vaccine 1&14, Vaccine + CpG-ODN 
1& CpG-ODN 14, Vaccine + Non CpG-ODN, and the control groups. Data from day 28 
revealed that animals in the group immunized with only the vaccine showed the highest 
IgG antibody levels, a difference (p<0.05) that was distinct from all other experimental 
groups (Table 1) 
Antibody levels in animals from Vaccine + CpG-ODN and Vaccine + Non CpG-
ODN 1 & Non CpG-ODN 14, were significantly different (p<0.05) from Vaccine 1&14, 
Vaccine + CpG-ODN 1& CpG-ODN 14, Vaccine + Non CpG-ODN, and the negative 
and challenge control groups. Levels in chickens from Vaccine + CpG-ODN 1&14 and 
Vaccine + Non CpG-ODN 1& 14 were not significantly different between themselves, 
but were higher (p<0.05) than the negative and the challenge controls. Results for day 31 
bleedings demonstrated that chicks which received the vaccine alone or the Vaccine + 
CpG-ODN on day-of-hatch and a boost with ODN and vaccine, show the highest levels 
of antibodies in peripheral blood, however they only differed (p<0.05) from Vaccine + 
CpG-ODN and the negative and challenge controls. Levels in animals in the rest of the 
experimental groups were not different from each other with the exception of the 
challenge and negative controls, which showed a lower IgG level.   
The third and final replicate trial was essentially the same experimental design as 
in the first replicate in that it consisted of the same experimental groups. However, the 
extra time point for bleeding on day 14 was included similar to replicate trial 2. 
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TABLE 1. Effect of NDV vaccine with or without CpG-ODN or Non CpG-ODN administration on serum IgG in SPF chickens 
vaccinated on day-of-hatch with a commercial NDV vaccine 
  Replica 1                             Replica 2     Replica 3 
Group    Day 28   Day 31         Day 14           Day 28           Day 31      Day 14                 Day 28            Day 31 
 
Vaccine  0.870±0.110c     1.132±0.145c 0.358±0.072ab   2.929±0.323a     2.218±0.158a 0.214±0.028b    1.630±0.177a   1.596±0.183a 
 
Vaccine               1.045±0.164c      1.279±0.140bc 0.034±0.006c     1.226±0.199c      1.742±0.246ab 0.206±0.029b    1.329±0.129ab  1.392±0.090a 
1&14 
 
V CpG  1.584±0.153b     1.587±0.179abc 0.311±0.076ab    1.908±0.256b     1.521±0.182b                    0.027±0.033b    1.477±0.194ab 1.277±0.141ab 
 
V CpG  3.316±0.167a     1.479±0.159bc 0.265±0.044ab    1.436±0.181bc     2.234±0.292a                    0.278±0.047b    1.383±0.176ab 1.298±0.134ab 
1&14  
 
V CpG  
1 & CpG 14                  0.044±0.073c      1.009±0.188c  1.660±0.217ab             
 
V N CpG 1.982±0.216b     1.780±0.157ab        0.028±0.057c    1.007±0.143c     1.864±0.153ab           0.251±0.032b    1.1777±0.102b   0.982±0.078b 
 
V N CpG  
1&14   1.796±0.200b      2.047±0.302a         0.271±0.063ab     1.449±0.170bc     2.035±0.276ab          0.427±0.077a    1.254±0.532ab    1.308±0.115ab 
 
V N CpG 
1 & Non CpG 14                  0.474±0.111a     1.836±0.204b      1.917±0.193ab                
 
Control 1              0.022±0.010d     0.027±0.003d        0.016±0.006c      0.036±0.005d      0.002±0.004c           0.023±0.009c     0.012±0.011c    0.014±0.002c 
 
Control 2 0.004±0.013d     0.0964±0.052d      0.013±0.012c      0.074±0.066d     0.082±0.085c           0.000±0.002c     0.005±0.004c    0.023±0.004c 
Data represent mean ±S.E. of antigen-specific IgG production 14, 28, or 31 post-vaccination in experimental animals for each experimental group. 
a,b.cMeans ±S.E. in columns within each column with no common superscript differ significantly (p<0.05). 
Treatments: Vaccine: Vaccine alone; Vaccine 1&14: Vaccine alone with boost on day 14; V CpG: Vaccine + CpG-ODN; V CpG 1&14: Vaccine + 
CpG-ODN with boost on day 14; V Non CpG: Vaccine + Non CpG-ODN; V Non CpG 1&14: Vaccine + CpG-ODN with boost on day 14; Control 1: 
Not vaccinated but challenged; Control 2: Not vaccinated not challenged.
   
 
54
Data from day 14 bleeding in this trial revealed that the chickens in the experimental 
group Vaccine + Non CpG-ODN 1& 14 had the highest (p<0.05) IgG level as compared 
to the remaining experimental groups (Table 1). Antibody levels in the challenge and 
negative experimental groups were significantly lower (p<0.05) than the remainder of 
the experimental groups. On day 28, collected data demonstrated that IgG levels from 
animals in the Vaccine alone group were the highest (p<0.05), but did not differ from the 
rest of the groups with the exception of Vaccine + Non CpG-ODN, and the controls. The 
rest of the groups do not differ from one another, but were higher (p<0.05) than observed 
levels in the control experimental groups. For the samples on day 31, levels in animals in 
Vaccine alone, and vaccine 1&14 experimental groups were different (p<0.05) from 
Vaccine + Non CpG-ODN and the negative controls. All remaining groups followed 
exactly the same trend as on day 28, with the exception that vaccine 1&14 differed 
(p<0.05) from the vaccine + Non CpG experimental group. 
Experiment 2  
 Experiment 2 compared the response of chickens vaccinated orally with a 
commercial live oocyst coccidial vaccine, with or without CpG-ODN or Non CpG-ODN 
administration. Birds were challenged 21 days post immunization with E. tenella and E. 
acervulina to evaluate protection against field strain challenge. Data obtained from 
lesion scoring all challenged animals for E. acervulina revealed that the negative control 
with challenge was the group with the highest (p<0.05) lesion score as compared to all 
other experimental groups. All groups not receiving challenge were significantly lower 
(p<0.05) than the challenged experimental groups. Lesions in the Coccivac + Non CpG 
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with challenge group were higher(p<0.05) than other experimental groups, with the 
exception of the Coccivac B + CpG with challenge group, which was not different with 
Coccivac B with challenge, but did vary (p<0.05) to the rest of the non challenged 
groups (Table 2). For E. tenella, the results show that all the lesions in animals from all 
challenged groups were markedly higher (p<0.05) when compared to the not challenged 
groups, but no difference was found when compared among challenged groups. All the 
non challenged groups did not differ from each other either (Table 2). Results in body 
weight gain from day 21 to day 27 showed that in the negative control without 
challenge, and the Coccivac B with challenge, there was a better (p<0.05) weight gain 
during challenge that what was observed in all other experimental groups, with the 
exception of Coccivac B group. Gain during challenge in the Coccivac B group was not 
different from Coccivac B + Non CpG-ODN with challenge. The rest of the 
experimental groups had a markedly lower (p<0.05) weight gain. Eimeria spp.-specific 
IgG antibodies on day 21 indicated that animals within the groups Coccivac B and 
Coccivac B with challenge had the highest (p<0.05) overall antibody levels in serum. 
Animals in the groups Coccivac B + CpG, Coccivac B + CpG with challenge, Coccivac 
B + Non CpG, and Coccivac B + Non CpG with challenge were all similar among 
themselves but differed (p<0.05) from the negative controls (challenged and not 
challenged). The negative controls had the lowest (p<0.05) observed values. On day 27 
the negative control group with challenge had the highest (p<0.05) levels of IgG 
measured in peripheral blood. Levels of IgG did not differ in all other experimental 
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groups with the exception of animals from the Coccivac B alone group, which had the 
lowest overall measured values. 
Experiment 3 
 In this experiment, day-of-hatch SCWL chickens were orally vaccinated and 
boosted with a commercial Salmonella vaccine consisting of a genetically modified S. 
typhimurium, with or without dual administration of CpG-ODN or Non CpG-ODN. Data 
obtained from day 14 bleedings revealed no measurable IgG level specific for either S. 
enteritidis or S. typhimurium in all experimental groups (data not shown). Antibody 
levels on day 28 and 35 increased in all groups. Observed values for S. enteritidis IgG 
levels for day 28 showed that the chickens within the Vaccine alone 1 & 14 experimental 
group had the highest (p<0.05) antibody levels as compared to other experimental 
groups(the table on page 59). Measured levels in Vaccine + CpG 1 &14 and Vaccine + 
Non CpG groups were notably higher (p<0.05) than values in vaccine alone and negative 
control groups, but not different from Vaccine + CpG and Vaccine + Non CpG 1 & 14 
groups. The samples obtained for S. typhimurium on day 28 showed that Vaccine + Non 
CpG 1 &14 IgG levels were considerably higher (p<0.05) than levels in vaccine + CpG, 
Vaccine + CpG 1&14, and the negative control, but not different from the experimental 
groups vaccine alone, vaccine 1&14, and vaccine + Non CpG. Further, IgG levels in the 
experimental group Vaccine 1&14 were higher (p<0.05) than the vaccine + CpG group 
and the negative control. Vaccine alone, Vaccine + CpG, Vaccine + CpG 1&14, Vaccine 
+ Non CpG were not different from negative controls. Samples obtained on day 35, 
when assayed for specific S. enteritidis IgG level, indicated 
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TABLE 2. Effect of a live oocyst coccidial vaccine with or without CpG-ODN or Non CpG-ODN administration on intestinal   
lesion score, body weight gain during challenge, or serum IgG response in broiler chickens vaccinated on day-of-hatch 
Lesion scores  Body Weight Gain*                     Serum IgG levels 
Group    EA         ET           EA&ET   Day 21      EAZS240       Day 27 
 
Negative Control  0±0e     0.179±0.074b    385.232±11.271a    0.077±0.010c        0.151±0.034b
  
 
Negative Control   2.154±0.1435a  1.885±0.128a  310.486±17.115c      0.061±0.008c        0.437±0.028a 
 With Challenge   
 
CoccivacB   0.222±0.082de  0.482±0.098b  367.404±7.889ab     0.330±0.030a        0.004±0.019c 
 
CoccivacB   0.777±0.097c  2±0.119a  382.826±9.459a     0.334±0.032a        0.090±0.011b 
With Challenge 
 
CoccivacB+ CpG  0.357±0.1056d  0.429±0.095b  329.196±8.707c     0.146±0.024b        0.093±0.010b 
 
CoccivacB + CpG  0.929±0.135bc  2.143±0.133a  326.614±17.359c     0.140±0.015b        0.119±0.016b 
 With Challenge 
 
CoccivacB + Non CpG  0.214±0.079de  0.321±0.089b  323.064±14.559c     0.165±0.021b        0.119±0.015b 
 
CoccivacB + Non CpG-ODN 1.214±0.157b  2.036±0.081a  337.364±9.533bc     0.159±0.018b        0.120±0.027b 
With Challenge 
Data represent mean ±S.E. of intestinal lesions scores, body weight gain during challenge, or antigen-specific IgG production 21 or 27 days post-
vaccination in experimental animals for each experimental group. 
a,b.cMeans ±S.E. in columns within each column with no common superscript differ significantly (p<0.05). 
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animals in the Vaccine + CpG group had the highest antibody levels, but were not 
different from other experimental groups with exception (p<0.05) of Vaccine + CpG 
1&14 and the negative control groups. Antibody levels in chickens in the Vaccine alone 
group differed (p<0.05) from the negative control group, but were not different from the 
remainder of the experimental groups. Additionally, there were no other differences 
among the rest of the groups. On day 35 when samples were analyzed for specific S. 
typhimurium IgG, levels in animals in the Vaccine 1&14, Vaccine + Non CpG, and 
Vaccine + Non CpG 1&14 groups were higher (p<0.05) than the negative controls, but 
not different from the remainder of the groups (Table 3). The rest of the groups were 
also not different from the negative control group. Bacterial recovery data revealed no 
differences among all experimental groups with regard to log10 CFU recovered from 
cecal contents for Salmonella enteritidis and S. typhimurium. Recovery following 
selective enrichment revealed differences in liver and spleen samples recovered from the 
S. typhimurium challenged birds from groups Vaccine 1 & 14, Vaccine + CpG-ODN 1 & 
14, Vaccine + Non CpG-ODN, and Vaccine + Non CpG-ODN 1 & 14 when compared 
to the rest of the experimental groups. Differences among S. typhimurium challenged 
chickens were not observed following selective enrichment of cecal samples. Similarly, 
differences were also not observed in either enriched liver and spleen, or cecal samples 
in S. enteritidis challenged chickens. (Table 4).
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TABLE 3. Effect of a gene modified-live Salmonella vaccine with or without CpG-ODN or Non CpG-ODN on serum IgG     
response in SCWL chickens vaccinated on day-of-hatch 
     Day 28      Day 35    Day 28     Day 35 
Group          Serum IgG S. enteritidis            Serum IgG S. typhimurium 
 
V    0.076±0.005c  0.189±0.017ab   0.072±0.023abc 0.137±0.030ab  
 
V 1&14   0.120±0.007a  0.159±0.011abc  0.129±0.017ab  0.230±0.038a   
 
V CpG    0.066±0.004bc  0.211±0.026a   0.055±0.007c  0.144±0.037ab  
 
V CpG 1&14   0.085±0.006b  0.141±0.016bc   0.063±0.009bc  0.149±0.033ab   
 
V Non CpG   0.086±0.014b  0.168±0.019abc  0.077±0.022abc 0.174±0.033a   
 
V Non CpG 1&14  0.078±0.005bc  0.175±0.018abc  0.141±0.041a  0.187±0.037ª   
  
Control   0.054±0.014c  0.120±0.015c   0.049±0.015c  0.051±0.012b   
Data represent mean ±S.E. of antigen-specific IgG production in serum 28 or 35 days post-vaccination in experimental animals for each 
experimental group. 
a,b.cMeans ±S.E. in columns within each column with no common superscript differ significantly (p<0.05). 
Treatments: V: Vaccine alone; V 1&14 Vaccine alone with boost on day 14; V CpG: Vaccine + CpG-ODN; V CpG 1&14: Vaccine + 
CpG-ODN with boost on day 14; V Non CpG: Vaccine + Non CpG-ODN; V Non CpG 1&14: Vaccine + CpG-ODN with boost on day 
14; Control: Not vaccinated. 
 
 
    
  
 
60
TABLE 4. Effect of a gene modified-live Salmonella vaccine with or without CpG-ODN or Non CpG-ODN on S. enteritidis     
or S. typhimurium cecal colonization or organ invasion response in SCWL chickens vaccinated on day-of-hatch 
   S. enteritidis    S. typhimurium 
Group  Liver & Spleen Ceca  Liver & Spleen Ceca         S. enteritidis log10       S. typhimurium log10 
V   3/11  11/11   4/12  12/12  2.323±0.55a  2.782±0.34a 
 
V 1&14  1/12  11/12   2/12*  11/12  2.323±0.55a  2.782±0.34a 
 
V CpG   1/12  12/12   6/12  12/12  2.924±0.58a  3.001±0.56a 
 
V CpG 1&14  2/11  11/11   1/12*  12/12  2.951±0.20a  2.751±0.35a  
 
V Non CpG  2/11  11/11   2/12*  11/12  3.034±0.42a  3.257±0.45a 
 
V Non CpG 1&14 1/11  11/11   2/12*  12/12  2.958±0.22a  3.578±0.54a 
 
Control   4/11  10/11   7/12  12/12  2.827±0.46a  2.532±0.47a 
Data represent incidence of S. enteritidis or S. typhimurium cecal colonization or liver / spleen invasion (number of animals positive for 
each respective bacterium per the total number of animals challenged per experimental group).  
*Indicates a statistically lower incidence level as compared to control (p<0.05).. 
Treatments: V: Vaccine alone; V 1&14 Vaccine alone with boost on day 14; V CpG: Vaccine + CpG-ODN; V CpG 1&14: Vaccine + 
CpG-ODN with boost on day 14; V Non CpG: Vaccine + Non CpG-ODN; V Non CpG 1&14: Vaccine + CpG-ODN with boost on day 
14; Control: Not vaccinated. 
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Experiment 4.   
 Experiment 4 was designed to evaluate two different doses for CpG-ODN: CpG-
ODN 50 (50 µg/bird) or CpG-ODN 75 (75µg/bird), and appropriate Non CpG-ODN 
controls (50µg/bird, and 75µg/bird), for effectiveness in immunization to BSA when 
administered orally as adjuvants in the drinking water. This experiment concurrently 
measured BSA-specific IgG levels in two different lines of chickens, SCWL and 
broilers, when bled on day 19 and 33 following the last day of immunization. The results 
observed in day 19 samples from post immunization SCWL chickens revealed that the 
BSA + CpG 50 group had higher (p<0.05) IgG levels when compared to the BSA + Non 
CpG 50, BSA + Non CpG 75, and the negative controls, but not different from BSA 
alone and BSA CpG 75 experimental groups (please refer to the table on page 64). 
Samples from the broiler chicks from the same sampling day indicated that that chickens 
from the BSA + CpG 75 group had markedly higher (p<0.05) circulating IgG levels 
when compared to the rest of the experimental groups with the exception of BSA + CpG 
50 and BSA+ Non-CpG 50. Levels in the BSA alone and BSA+ Non-CpG 75 were 
higher than levels measured in the negative controls, but not different than levels in the 
BSA +CpG 50 and BSA + Non CpG 50 groups. The negative control group was 
observed to have the lowest (p<0.05) IgG levels among all the experimental groups. 
Samples obtained from SCWL on day 33, revealed IgG levels in chickens in the BSA + 
CpG 75 to be higher than all other experimental group with the exception of BSA alone 
experiment group. However, the BSA alone group did not differ from BSA + CpG 50, 
but differed (p<0.05) from the rest of the experimental groups. BSA + CpG 50 levels 
  
  
 
62
were not notably different from BSAN on CpG 50 and BSA Non CpG 75. Antibody 
levels in negative control animals were again the lowest (p<0.05) observed in all groups. 
Serum IgG levels measured in broiler chickens on day 33 post immunization reveled no 
significant differences among all experimental groups with the exception of the negative 
controls, which were the lowest (p<0.05) of the remainder of the experimental groups.  
Discussion 
 Experiment 1 of the present study was designed to investigate the potential for 
CpG-ODN to adjuvant a commercial NDV vaccine when applied by an ocular and 
intranasal route to neonatal SPF chickens. With the exception of replicate trial 1, across 
the other replicate trials, data were variable in terms of describing any possible 
enhancement of a humoral response in CpG-ODN or Non CpG-ODN treated chickens. 
Replicate trial 1 clearly demonstrated an enhanced humoral response associated with 
CpG-ODN administration, especially on day 28 of this trial (Table 1). Both within this 
trial and throughout other experiments of this study, stimulatory effects of Non CpG-
ODN administration were observed. These trends were not reinforced, however, in 
replicate trials 2 and 3 (Table 1). Surprisingly, in these trials, the highest overall NDV 
IgG levels in animals across all experimental groups were measured in chickens in the 
vaccine alone group that did not receive a booster vaccination on day 14 (Table 1). Even 
though we could speculate that there is interference of some of the vaccine components 
with the ODN, there is no explanation as to why the group vaccine alone with boost had 
different results even before receiving the boost. Therefore, after a great deal of 
consideration of these variable results from experiment 1, we can not provide a 
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reasonable explanation for these observations. Further studies need to be done. As an 
observation, a specific ELISA to measure different isotypes in serum, and possibly 
within respiratory mucosa should be performed instead of using a commercial kit. 
 Experiment 2 evaluated the potential for CpG-ODN to adjuvant a commercial 
live oocyst coccidial vaccine when applied by an oral route to neonatal broiler chickens. 
Overall, when body weight gain during challenge, development of clinical lesions, and 
anti-Eimeria IgG levels were evaluated, vaccine administration alone was demonstrated 
to provide the best measure of protection among animals in all experimental groups, 
including those receiving either CpG-ODN or Non CpG-ODN. Given the well 
documented emphasis on the involvement of cell mediated immunity (CMI) in the 
generation of complete immunity in chickens to Eimeria immunization and challenge 
(please see Chapter II), an obvious criticism of the experimental design of experiment 2 
would be that a measure of some CMI index may have resulted in different, possibly 
more positive observations associated with ODN administration. It bears consideration 
however that this might be over speculation since measurement of performance 
parameters revealed that animals receiving ODN administration along with the vaccine 
did not perform as well as animals which received vaccine alone. Interestingly, the 
observation of anti-Eimeria IgG levels being depressed at six-days post- E. acervulina 
and E. tenella challenge, as compared to levels measured on day 21, while 
unexplainable, is interesting. The only experimental animals among all experimental 
groups that were observed to have increased the anti-Eimeria IgG levels during 
challenge were in the negative control and negative control with challenge groups. 
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TABLE 5. Effect of BSA immunization through the drinking water with or without CpG-ODN or Non CpG-ODN on serum 
IgG response in SCWL or broiler chickens 
      Day 19      Day 33    Day 19  Day 33 
Group/Treatment              Serum IgG vs. BSA      Serum IgG vs. BSA  
                       SCWL       B R O I L E R S 
 
BSA Only    0.629±0.054ab  0.954±0.040ab   0.479±0.041b  0.657±0.060a 
 
BSA. + CpG-ODN 50    0.730±0.040a  0.871±0.050bc   0.529±0.042ab  0.756±0.060a 
 
BSA + CpG-ODN 75     0.610±0.098ab  1.016±0.043a   0.664±0.070a  0.751±0.060a 
 
BSA + Non CpG-ODN 50  0.530±0.033b  0.776±0.032c   0.567±0.064ab  0.771±0.067a 
 
BSA + Non CpG-ODN 75  0.550±0.048b  0.768±0.036c   0.465±0.050b  0.778±0.050a 
 
Negative Control   0.024±0.029c  0.003±0.001d   0.049±0.008c  0.049±0.017b 
Data represent mean ±S.E. of antigen-specific IgG production in serum 19 or 33 days post-last day of immunization in experimental 
animals for each experimental group. 
a,b.cMeans ±S.E. in columns within each column with no common superscript differ significantly (p<0.05). 
CpG-ODN 50 or Non CpG-ODN 50 refers to administration of 50 µg CpG-ODN or Non CpG-ODN, respectively. 
CpG-ODN 75 or Non CpG-ODN 75 refers to administration of 75 µg CpG-ODN or Non CpG-ODN, respectively. 
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The fact that negative control animals, in this case responding within six days with such 
magnitude in terms of an IgG response, suggests some degree of cross-contamination 
among pens within the brooder battery by vaccine or challenge oocysts occurred. In 
support of this, five experimental animals in the non-challenged negative control 
experimental group were observed to have cecal lesions, albeit at a very low level, 
consistent with E. tenella infection. Nonetheless, additional investigation into these 
phenomena would likely add clarity to our poor understanding of the results of this 
specific experiment. Evaluation of different isotypes present in serum, gut and bile 
should be analyzed. A different way of housing in order to avoid cross contamination is 
also recommended. 
 Experiment 3 investigated the effectiveness of the co-administration of CpG-
ODN or non-CpG ODN and a commercially acquired Salmonella typhimurium vaccine 
for effects on stimulating antigen-specific IgG levels and protection against field strain 
Salmonella challenge. Similar to experiments 1 and 2, experiment 3 also demonstrated 
variable results in IgG levels specific for S. typhimurium or S. enteritidis associated with 
either CpG-ODN or Non CpG-ODN and vaccine groups, when compared to vaccine 
alone groups. Examples include the single vaccine and CpG-ODN co-administration S. 
enteritidis-IgG levels being elevated on day 35 of this experiment, despite being not 
different (p<0.05) from vaccine alone controls (Table 3). Additionally, experimental 
animals in the vaccine + Non CpG-ODN experimental group had similarly high anti-S. 
typhimurium IgG levels on both days 28 and 35 of this experiment, but again, these 
levels were not distinguishable from vaccine alone controls (Table 3). Protection against 
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field strain challenge revealed a somewhat more positive observation associated with 
Non CpG-ODN and vaccine co-administration (Table 4). When protection against S. 
typhimurium organ invasion was assessed in animals in all experimental groups, 
significant protection was observed in the vaccine with boost, CpG-ODN with vaccine 
and boost, Non CpG-ODN with vaccine, and the Non CpG-ODN with vaccine and boost 
experimental groups. While most animals in these experimental groups were vaccinated 
twice, both initially on day-of-hatch and then with a booster administration on day 14, 
the non-CpG with vaccine experimental group was the only group associated with 
significant protection against S. typhimurium organ invasion that received vaccine only 
once (Table 4). Again, as with our conclusions related to observations from experiments 
1 and 2, data from the present experiments demonstrated variable results related to the 
co-administration of ODN and vaccine, which were often indistinguishable from results 
observed in animals receiving vaccine alone.  
 Anti-BSA IgG levels were compared in broiler and SCWL chickens immunized 
against BSA by a drinking water route of administration alone, or in combination with 
two concentrations of CpG-ODN or Non CpG-ODN in experiment 4. Although there 
were a number of suggestive trends for increased antibody production due to co-
administration of CpG-ODN + BSA, such as the difference in SCWL chickens 
associated with the administration of CpG-ODN at 50 µg/chicken for day 19 IgG levels 
and the CpG-ODN at 75 µg/chicken for day 33 IgG levels, these values were not 
distinguishable from animals administered BSA alone. The only observation where 
CpG-ODN and BSA co-administration resulted in anti-BSA IgG levels that were 
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elevated above BSA alone immunized chickens, was measured in broilers for the day 19 
time point. While it is tempting to suggest that broilers and SCWL chickens responded 
differently to the administration of CpG-ODN in this experiment, since CpG-ODN and 
BSA co-administration to broilers revealed the only elevation in anti-BSA IgG level 
statistically distinguishable from BSA alone controls, further investigation into 
comparing these and similar effects is clearly needed before such characterizations can 
be made. Such differences in immunoresponsiveness are supported in the literatures as 
Leshchinsky and co-worker (Leshchinsky and Klasing, 2001) reported that two genetic 
types of chickens (broilers and SCWL) clearly exhibit different capacities for generating 
immune response. Taken together, while suggestive in certain specific areas within and 
across experiments in the present investigation, these data are largely inconclusive for 
suggesting that CpG-ODN can effectively adjuvant humoral immune responses to 
commercial vaccines or protein antigens in commercial strain chickens. 
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CHAPTER IV 
 
CONCLUSIONS 
 
To control disease conditions under the dense and intensive rearing conditions of 
commercial poultry production, vaccines represent an important and invaluable 
prophylactic and therapeutic strategy for commercial producers (Sharma, 2003). The 
commercial poultry industry relies heavily vaccines to protect chickens and turkeys 
against many pathogens that threaten poultry health and the subsequent overall 
economics of the industry. The fundamental task of the immune system in responding to 
vaccination is to generate protection in the host against invading microorganisms or 
pathogens through a cooperative approach involving both innate and adaptive immunity. 
Innate immune responses are typically activated by innate system cells, such as 
macrophages, heterophils, or dendritic cells, which then act in concert to either kill the 
invading microbe or augment and trigger an appropriate adaptive immune response. 
Because innate immune cells lack the highly specific antigen receptors found on T and B 
cells they rely on surface membrane proteins known as pattern recognition receptors 
(PRRs). PRRs have the ability to detect surface components of microbial pathogens 
known as pathogen associated molecular patterns (PAMPs). PAMPs recognition by 
PRRs in this setting is an indication of a threat to the host in the form of potential 
infection. Such recognition activates appropriate defense pathways in the innate system 
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to either remove the pathogen or stimulate the adaptive system to act upon the pathogen 
for its ultimate removal.  
CpG motifs naturally present in bacterial DNA represent one of the most recent 
examples of substances that influence adaptive immune responses by activating the 
innate immune system. CpGs are 6-8 base nucleotide motifs consisting of an 
unmethylated CpG dinucleotide that induce cells of the innate immune system to 
increase phagocytosis, pro-inflammatory cytokine production, activation of NK cells, 
increase nitric oxide generation by macrophages, and stimulate B cell proliferation and 
differentiation. The ability of CpG-ODN to act as vaccine adjuvants has been explored 
extensively in recent years in mammals but very little research has been conducted along 
these lines in commercial poultry. In recent years, DNA vaccines or DNA extracts from 
bacteria have been recognized as having tremendous potential for improving vaccination 
strategies in commercial poultry against different pathogens. The objective of this 
investigation was to evaluate the administration of CpG-ODN as a potential oral 
adjuvant to commercially available vaccines against Salmonella, Eimeria spp., and 
NewcastleDisease Virus, and a common protein antigen, bovine serum albumin (BSA). 
Measured experimental outcomes included the level of antibodies produced and 
protection against subsequent clinical challenge in experimental animals following 
immunization and vaccination procedures evaluated in this study. 
 Experiment 1 of the present study was designed to investigate the potential for 
CpG-ODN to adjuvant a commercial NDV vaccine when applied by an ocular and 
intranasal route to neonatal SPF chickens. With the exception of replicate trial 1, across 
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the replicate trials, data were variable in terms of describing any possible enhancement 
of a humoral response in CpG-ODN or Non CpG-ODN treated chickens. Replicate trial 
1 clearly demonstrated an enhanced humoral response associated with CpG-ODN 
administration, especially on day 28 of this trial (Table 1). Both within this trial and 
throughout other experiments of this study, stimulatory effects of Non CpG-ODN 
administration were observed. These trends were not reinforced, however, in replicate 
trials 2 and 3 (Table 1). Surprisingly, in these trials, the highest overall NDV IgG levels 
in animals across all experimental groups were measured in chickens in the vaccine 
alone group that did not receive a booster vaccination on day 14 (Table 1). Since the 
vaccine administered to each chicken during the three trials was given by the same 
person, under the same conditions with the same vaccine and the same dose. And since 
in some cases the vaccine alone experimental group had a good response, but the vaccine 
alone with a boost experimental groups, before receiving the boost had significantly 
different results, we can not provide a reasonable explanation for these observations. 
 Experiment 2 evaluated the potential for CpG-ODN to adjuvant a commercial 
live oocyst coccidial vaccine when applied by an oral route to neonatal broiler chickens. 
Overall, when body weight gain during challenge, development of clinical lesions, and 
anti-Eimeria IgG levels were evaluated, vaccine administration alone was demonstrated 
to provide the best measure of protection among animals in all experimental groups, 
including those receiving either CpG-ODN or Non CpG-ODN. Given the well 
documented emphasis on the involvement of cell mediated immunity (CMI) in the 
generation of complete immunity in chickens to Eimeria immunization and challenge 
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(please see Chapter II), an obvious criticism of the experimental design of experiment 2 
would be that a measure of some CMI index may have resulted in different, possibly 
more positive observations associated with ODN administration. It bears consideration 
however that this might be over speculation since measurement of performance 
parameters revealed that animals receiving ODN administration along with the vaccine 
did not perform as well as animals which received the vaccine alone. Nonetheless, 
additional investigation into these phenomena would likely add clarity to our poor 
understanding of the results of this specific experiment. 
 Experiment 3 investigated the effectiveness of the co-administration of CpG-
ODN or Non CpG-ODN and a commercially acquired Salmonella typhimurium vaccine 
for effects on stimulating antigen-specific IgG levels and protection against field strain 
Salmonella challenge. Similar to experiments 1 and 2, experiment 3 also revealed 
variable results in terms of elevated IgG levels specific for S. typhimurium or S. 
enteritidis associated with either CpG-ODN or Non CpG-ODN and vaccine co-
administration, when compared to vaccine alone groups (Table 3). Protection against 
field strain challenge revealed a somewhat positive observation associated with Non 
CpG-ODN and vaccine co-administration (Table 4). While most animals in these 
experimental groups were vaccinated twice, both initially on day-of-hatch and then with 
a booster administration on day 14, the non-CpG with vaccine experimental group was 
the only group associated with significant protection against S. typhimurium organ 
invasion that received vaccine only once (Table 4). Again, as with our conclusions 
related to observations from experiments 1 and 2, data from the present experiments 
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demonstrated variable results related to the co-administration of ODN and vaccine which 
were often indistinguishable from results observed in animals receiving vaccine alone.  
Anti-BSA IgG levels were compared in broiler and SCWL chickens immunized against 
BSA by a drinking water route of administration alone, or along with the co-
administration of two concentrations of CpG-ODN or Non CpG-ODN in experiment 4. 
Although there are a number of suggestive trends for increased antibody production due 
to co-administration of CpG-ODN and BSA the only observation where CpG-ODN and 
BSA co-administration resulted in anti-BSA IgG levels that were elevated above BSA 
alone immunized chickens was measured in broilers for the day 19 time point. Taken 
together, while suggestive in certain specific areas within and across experiments in the 
present investigation, these data are largely inconclusive for suggesting that CpG-ODN 
can effectively adjuvant humoral immune responses to commercial vaccines or protein 
antigens in commercial strain chickens. 
Until recently, there were only a few experiments that evaluated the effects of 
CpG-ODN as potential adjuvants in poultry. These experiments included a study into the 
efficacy of CpG-ODN against IFA by comparing their efficacy in producing IgG and 
IgM after being injected subcutaneously with BSA in chickens. Observed results showed 
that antibody levels were higher in chickens injected with both CpG-ODN and BSA, 
suggesting a possible adjuvant effect via the subcutaneous route of administration 
(Vleugels et al., 2002). A second study evaluated the proliferation of PBMC in 
peripheral blood in 6 chickens with different sequences and backbones of CpG-ODN. 
Despite an obvious criticism of using such a limited number of experimental animals, 
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the results of this experiment indicated that a sequence with 3 CPG motifs in the same 
ODN (sequence number 2135) was the most immunostimulatory (Rankin et al., 2001). 
Another study by Gomis and co-workers represents essentially the only complete report 
on a study performed in vivo in chickens to date. This group evaluated the administration 
route and the specific protection against E. coli infection induced by CpG-ODN when 
inoculated to birds via SC or IM administration (Gomis et al., 2003). 
There were different deficiencies in the experimental approach taken in this 
investigation. Consideration of these for further studies need to be evaluated. For 
example, the evaluation of just a single sequence of CpG-ODN and Non CpG-ODN was 
inappropriate. Different sequences of CpG-ODN and Non CpG-ODN, including the ones 
utilized in this investigation, should be evaluated, since there was a similar response of 
Non CpG-ODN sequence with the CpG-ODN. Different timings of the administration of 
the ODN, prior and after immunization or vaccination need to be evaluated. The 
measurement of only a single isotype of secreted antibody in experimental animals 
resulted in an incomplete evaluation of the chicken’s immune response towards the 
adjuvants and the vaccination or immunization, therefore different isotypes, local and 
systemic, also need to be investigated. Since our objective was to evaluate the CpG-
ODN as a mucosal adjuvant, known adjuvants should be used as a control. Even though 
the performance of the birds was not improved, it would be interesting to measure some 
parameters of cell mediated immunity (evaluation of cytokine expression, specifically 
IFNγ, and IL6) to provide additional insight into observed responses elicited by ODN 
administration. Future studies should be designed with these observations in mind before 
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additional conclusions can be made related to the potential usefulness of ODN 
administration for immunostimulation of commercial poultry. 
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